Bovine Respiratory Syncytial Virus

Overview and Taxonomy of Bovine Respiratory Syncytial Virus

Bovine respiratory syncytial virus (BRSV) is a globally significant, enveloped, negative-sense, single-stranded RNA virus belonging to the family Pneumoviridae, genus Orthopneumovirus [1, 3, 13]. This taxonomic classification, updated from the former Paramyxoviridae family, places BRSV in close genetic and antigenic kinship with human respiratory syncytial virus (HRSV), the leading cause of severe lower respiratory tract infections in infants and the elderly worldwide [1, 3, 21]. The virus is a primary etiological agent within the bovine respiratory disease complex (BRDC), a multifactorial syndrome that constitutes the most significant health and economic challenge for the global cattle industry, resulting in substantial morbidity, mortality, reduced productivity, and increased costs associated with treatment and prevention [1, 3, 6, 13]. The World Organisation for Animal Health (WOAH) recognizes BRSV as a critical pathogen impacting livestock health and international trade, underscoring its importance in veterinary public health and food security.

Taxonomic Position and Phylogenetic Relationships

The reclassification of RSV from the Paramyxoviridae to the Pneumoviridae family was a significant taxonomic revision, reflecting fundamental differences in genome organization, replication strategy, and protein function from other paramyxoviruses [1, 3]. Within the Orthopneumovirus genus, BRSV is a distinct species, yet it shares a remarkable degree of homology with HRSV, particularly in the structure and function of key proteins such as the fusion (F) and attachment (G) glycoproteins [1, 21]. This high level of conservation has profound implications for translational research, as BRSV infection in its natural bovine host recapitulates the pathogenesis, clinical signs, and immune responses of HRSV infection in humans far more faithfully than semi-permissive rodent models [1, 3, 12, 21]. Consequently, the calf is recognized as a highly relevant and validated animal model for studying RSV pathogenesis, evaluating antiviral compounds, and testing novel vaccine strategies for human medicine [3, 12, 20, 22].

Phylogenetic analyses, primarily based on the highly variable G glycoprotein gene, have delineated BRSV into multiple genetic subgroups, with at least eight (I through VIII) recognized globally [14, 17]. The G protein is the primary target for neutralizing antibodies and is under significant immune selection pressure, driving the evolution and diversification of the virus [7, 9, 17]. Subgroup III is currently the most widely distributed and dominant genotype, having been identified as the primary circulating strain in North America, China, Turkey, and Brazil [7, 9, 10, 14, 15]. For instance, extensive surveillance in China from 2020 to 2022 revealed that all 18 complete G gene sequences obtained from 11 provinces clustered within subgroup III, indicating its predominance in Chinese beef cattle populations [7]. Similarly, studies in Turkey have consistently identified subgroup III strains circulating in both dairy and beef herds, often with unique amino acid substitutions in the G protein that suggest ongoing regional evolution [9, 15, 16].

However, the genetic landscape of BRSV is dynamic and geographically complex. In Europe, a more heterogeneous distribution is observed. For example, a longitudinal study in Croatia from 2011 to 2016 documented the circulation of strains from subgroups II, VII, and a newly identified subgroup VIII, with a temporal shift from subgroup VII to VIII over the study period [17]. In contrast, Norwegian outbreaks have been predominantly associated with subgroup II strains, which cluster with other North European isolates [24]. This geographic and temporal clustering suggests that BRSV evolution is influenced by local host population dynamics, vaccination practices, and animal movement patterns [8, 24]. Critically, the emergence of novel subgroups, such as the putative new subgroup identified in Brazilian wild-type strains, which harbors mutations in the immunodominant central hydrophobic region of the G protein, highlights the continuous evolutionary pressure on the virus and the potential for antigenic drift that could impact vaccine efficacy [14].

Virion Structure and Genomic Organization

The BRSV virion is pleomorphic, typically spherical or filamentous, with a diameter ranging from 80 to 350 nm, and is enveloped by a lipid bilayer derived from the host cell plasma membrane [3, 13]. The viral genome is a non-segmented, negative-sense RNA molecule of approximately 15,000 nucleotides, which encodes 11 known proteins [1, 4]. The genome follows a conserved gene order: 3′-NS1-NS2-N-P-M-SH-G-F-M2-1/M2-2-L-5′ [1, 13]. The ribonucleoprotein (RNP) core consists of the genomic RNA tightly encapsidated by the nucleoprotein (N), along with the phosphoprotein (P) and the large polymerase subunit (L), which together form the functional RNA-dependent RNA polymerase complex [1, 3].

The viral envelope is studded with three transmembrane glycoproteins: the attachment protein (G), the fusion protein (F), and the small hydrophobic (SH) protein [1, 3, 18]. The G protein is a heavily glycosylated type II transmembrane protein responsible for initial attachment of the virus to the host cell surface, likely via interaction with glycosaminoglycans [2, 3]. The F protein is a type I transmembrane protein that mediates fusion of the viral envelope with the host cell membrane, a critical step for viral entry [3, 19]. The F protein exists in a metastable prefusion conformation that, upon activation, undergoes a dramatic conformational rearrangement to drive membrane fusion. Neutralizing antibodies targeting both the prefusion and postfusion forms of F are critical for protective immunity, with the prefusion form being the primary target of highly potent neutralizing antibodies [5, 19]. The SH protein, a small viroporin, is not essential for viral replication in vitro but plays a crucial role in pathogenesis by modulating the host immune response. Specifically, the SH protein has been shown to inhibit NF-κB p65 phosphorylation, thereby suppressing the production of pro-inflammatory cytokines and interfering with the activation of antigen-presenting cells [18]. Deletion of the SH gene (rBRSVΔSH) results in a virus that induces higher levels of apoptosis and pro-inflammatory cytokines in vitro and is attenuated in the lower respiratory tract of calves, yet remains highly immunogenic, making it a promising candidate for a live-attenuated vaccine [18, 23].

Antigenic Diversity and Immune Evasion

The genetic diversity observed among BRSV subgroups translates into antigenic differences, particularly within the G protein, which contains a central conserved region (CCR) flanked by two highly variable mucin-like regions [7, 14]. The CCR is a major antigenic site, and mutations within this region, such as those observed in Brazilian and Turkish isolates, can alter antibody reactivity and potentially facilitate immune escape [9, 14]. The F protein, while more conserved than G, also exhibits some antigenic variation, and the balance between antibodies targeting prefusion versus postfusion F conformations is critical for neutralization potency [5, 19].

BRSV has evolved sophisticated mechanisms to subvert the host immune response, contributing to its ability to cause repeated infections throughout an animal’s life and the suboptimal efficacy of some vaccines [1, 5]. Beyond the SH protein’s modulation of NF-κB signaling, BRSV non-structural proteins NS1 and NS2 are potent antagonists of the type I interferon (IFN) response. They act by inhibiting the induction and signaling of IFN-α/β, thereby blunting the establishment of an antiviral state in infected cells [1, 11]. This suppression of the innate immune response is a key factor in the virus’s ability to replicate efficiently and cause disease. Furthermore, the virus can interfere with the function of dendritic cells and macrophages, impairing antigen presentation and the subsequent activation of adaptive T cell responses [1, 18]. This multifaceted immune evasion strategy explains why natural infection often fails to induce robust, long-lasting sterilizing immunity, and why reinfections are common, even in adult cattle with pre-existing antibodies [5, 25]. The interplay between these viral evasion proteins and the host’s innate and adaptive immune systems is a central area of research, as understanding these mechanisms is crucial for the rational design of more effective vaccines and therapeutics [1, 11, 18].

Molecular Pathogenesis and Immune Evasion Mechanisms

Bovine respiratory syncytial virus (BRSV), an Orthopneumovirus within the Pneumoviridae family, represents a pathogen of paramount importance to global cattle health and productivity. The virus is a primary etiological agent within the bovine respiratory disease complex (BRDC), and its economic impact, recognized by the World Organisation for Animal Health (WOAH) and the Food and Agriculture Organization (FAO) as a significant constraint to livestock production, stems from its ability to cause severe bronchiolitis and interstitial pneumonia, particularly in young calves [1, 3, 13]. The molecular pathogenesis of BRSV is a multifaceted process, arising from a dynamic and often antagonistic interaction between the virus and the host’s respiratory epithelium and immune system. Critically, BRSV has evolved a sophisticated arsenal of immune evasion strategies that subvert both innate and adaptive arms of the host response, facilitating viral replication, driving immunopathology, and frustrating the development of long-lived, sterilizing immunity [1, 21]. Understanding these molecular mechanisms is not only fundamental to virology but is also essential for developing rational, next-generation vaccines and therapeutics to control this pervasive pathogen.

Viral Entry, Cellular Tropism, and Cytopathology

The initial stage of BRSV pathogenesis is defined by its tropism for the ciliated epithelial cells of the respiratory tract. Following aerosol or direct-contact transmission, the virus initiates infection in the upper respiratory tract (nasal epithelium, trachea) before progressing to the lower respiratory tract, including the bronchioles and alveoli [1, 38]. The viral fusion (F) glycoprotein is the primary driver of both viral attachment and membrane fusion, a process that occurs at the cell surface or within endosomal compartments [5, 21]. While the attachment (G) glycoprotein is critical for binding to cellular glycosaminoglycans, the F protein’s ability to undergo a dramatic conformational rearrangement from a metastable prefusion form to a stable postfusion form is the central event that enables the viral envelope to merge with the host cell membrane, delivering the viral ribonucleoprotein complex into the cytoplasm [5, 21]. Studies using monoclonal antibodies have demonstrated that passive transfer of neutralizing antibodies targeting specific epitopes on the F protein, particularly those unique to the prefusion conformation, can confer protection in calves, highlighting this protein as a critical target for vaccine-induced immunity [21]. The virus demonstrates a pronounced tropism for the lower respiratory tract; in vitro studies using bovine epithelial cell lines derived from the trachea (bTEC), bronchus (bBEC), and lung (bLEC) have shown that cells from the lower tract (bBEC and bLEC) are significantly more susceptible to BRSV infection than those from the upper tract [31]. This differential susceptibility is a key factor in the virus’s ability to establish a productive infection in the deep lung, leading to the characteristic pathological lesions of bronchiolitis and interstitial pneumonia [27, 38].

Once inside the host cell, BRSV replication leads to profound cytopathological effects. The formation of multinucleated syncytia, a hallmark of paramyxovirus and pneumovirus infections, is driven by the F protein expressed on the surface of infected cells, which fuses the plasma membrane with adjacent, uninfected cells [15, 27, 38]. This process facilitates direct cell-to-cell spread of the virus, effectively evading the extracellular milieu. Histopathological examination of infected lung tissue reveals epithelial necrosis, with the loss of ciliated cells and the sloughing of the epithelial lining into the bronchiolar and alveolar lumens [29, 38]. This damage compromises the mucociliary escalator, a critical innate defense mechanism, and creates an environment ripe for secondary bacterial invasion [1, 2]. The virus also infects and activates alveolar macrophages, a key sentinel cell of the innate immune system. While infection of macrophages can be non-productive, it profoundly alters their function, impairing their phagocytic capacity and triggering the release of a cascade of pro-inflammatory mediators that contribute to the extensive inflammation observed in the lung [21, 38].

Modulation of the Host Innate Immune Response and Induction of Oxidative Stress

Upon entry, BRSV is recognized by pattern recognition receptors (PRRs) of the innate immune system, including Toll-like receptors (TLRs) and RIG-I-like receptors (RLRs), which trigger signaling cascades leading to the production of type I interferons (IFN-α/β) and pro-inflammatory cytokines [1]. However, BRSV has evolved multiple mechanisms to cripple this first line of defense. A pivotal immune evasion strategy is centered on the small hydrophobic (SH) viroporin. The SH protein, an integral membrane protein with ion channel activity, acts as a potent inhibitor of the NF-κB signaling pathway, a master regulator of the inflammatory response. Work using a recombinant BRSV lacking the SH gene (rBRSVΔSH) has been illuminating. In contrast to wild-type virus, rBRSVΔSH infection of bovine antigen-presenting cells (monocytes, macrophages, dendritic cells) results in enhanced phosphorylation of the NF-κB p65 subunit, leading to significantly higher production of pro-inflammatory cytokines (e.g., TNF-α, IL-1β) and increased T-cell activation [18]. This demonstrates that the SH protein directly dampens the innate immune response, blunting the host’s ability to mount an early, robust anti-viral state. Furthermore, the ΔSH virus induces higher levels of apoptosis in infected epithelial cells and monocytes in vitro and is significantly attenuated in the lower respiratory tract of calves, inducing a markedly reduced pulmonary inflammatory response despite its greater intrinsic immunogenicity [23]. This highlights a critical balance: the SH protein not only evades immunity but also directly contributes to viral fitness by dampening a potentially harmful, but virus-clearing, inflammatory response.

In addition to direct signaling interference, BRSV infection triggers a profound perturbation of the cellular redox balance, leading to oxidative stress. Transcriptional analysis of BRSV-infected bovine respiratory cells, both in vitro and ex vivo, reveals significant upregulation of genes involved in reactive oxygen species (ROS) production, including prostaglandin-endoperoxide synthase 2 (PTGS2) and dual oxidases (DUOX1 and 2) [32]. PTGS2 expression, in particular, more than doubled in both cell types and lesion-adjacent lung tissue [32]. This oxidative burst, while a component of the host’s antimicrobial defense, becomes dysregulated during BRSV infection. Analysis of the bronchoalveolar lavage (BAL) proteome from infected calves confirms a state of severe oxidative disequilibrium, characterized by a reduction in antioxidant enzymes and evidence of neutrophil activation and elastin degradation [36]. The formation of neutrophil extracellular traps (NETs), as indicated by the presence of citrullinated histone 3, is a specific pathogenic mechanism observed only in non-vaccinated, BRSV-infected calves [36]. These NETs, while intended to trap pathogens, can also damage lung tissue, contributing to airway obstruction and the severity of disease. The exaggerated neutrophil response and associated release of ROS are therefore not simply a consequence of infection but a critical driver of the immunopathology characteristic of severe BRSV bronchiolitis [12, 36]. This link is so strong that beta-carotene supplementation aimed at bolstering the antioxidant capacity has been explored as a means to mitigate disease [37].

Facilitation of Secondary Bacterial Infection

A major component of BRSV’s pathogenic success is its ability to predispose the host to life-threatening secondary bacterial pneumonia, a phenomenon that is a central feature of the BRDC [1, 33]. BRSV does not simply damage the epithelium, creating a physical breach; it actively and specifically enhances the adherence of key bacterial pathogens at a molecular level. This synergy is a classic example of viral-bacterial co-pathogenesis.

The mechanisms are remarkably sophisticated and site-specific. In the lower respiratory tract (bronchus and lung), BRSV infection has been shown to dramatically increase the adherence of Pasteurella multocida to epithelial cells [31, 35]. This enhancement is mediated by the virus’s ability to upregulate the expression of the platelet-activating factor receptor (PAFR) on the surface of infected bronchial and lung epithelial cells [30]. PAFR serves as a critical adhesion receptor for P. multocida, and blockade, knockdown, or overexpression of this receptor directly correlates with the level of bacterial adherence [30]. Concurrently, in a seemingly opposing but complementary mechanism in the upper respiratory tract, BRSV infection decreases the expression of intercellular adhesion molecule-1 (ICAM-1), which is a primary receptor for P. multocida adherence on upper respiratory epithelial cells [34]. This downregulation may serve to depress bacterial clearance in the upper airways, shunting the bacterial inoculum towards the lower tract where the virus has already primed the epithelium for enhanced binding via PAFR, thereby synergistically driving severe pneumonia.

For another key bacterial opportunist, Trueperella pyogenes, BRSV employs a different molecular strategy. BRSV infection significantly enhances T. pyogenes adhesion to a variety of cell types in a multiplicity-of-infection- and time-dependent manner [2]. Remarkably, this effect is mediated directly by the BRSV G glycoprotein itself. When the G protein is expressed on the cell surface (either by infection or transfection), it acts as a direct adhesion molecule for T. pyogenes. Immunofluorescence assays have confirmed the colocalization of the G protein and the bacteria on the infected cell membrane, and pre-incubation with anti-G antibodies effectively blocks the enhanced adherence [2]. This represents a novel and direct role for a viral attachment protein in promoting secondary bacterial infection, transforming the BRSV-infected cell into a platform for bacterial colonization.

Subversion of the Adaptive Immune Response and Long-Term Persistence

While the innate immune response is heavily targeted, BRSV also erects barriers to the development of effective adaptive immunity. The antibody response, particularly neutralizing antibodies against the F and G proteins, is a known correlate of protection against severe disease, yet reinfections throughout an animal’s life are common [5, 25]. Several factors contribute to this. The G protein, in particular, exhibits significant genetic and antigenic variability. Phylogenetic analyses of circulating BRSV strains worldwide have classified them into multiple subgroups (e.g., I through VIII), with new subgroups (VII, VIII) and putative novel clades emerging [14, 17]. The G protein’s central hydrophobic region, an immunodominant domain, is a hotspot for amino acid substitutions, including the loss of conserved cysteine residues that can alter the protein’s conformation and antibody reactivity [14, 17]. This constant antigenic drift, driven by selective pressure from the host immune response, allows variant strains to escape pre-existing neutralizing antibodies, explaining why animals can be re-infected with BRSV throughout their lives, even in the face of prior immunity [5, 24]. The memory response is also skewed; following natural infection, the systemic recall response to re-challenge is significantly stronger against the prefusion form of the F protein compared to the postfusion form, suggesting that vaccine strategies should focus on stabilizing the prefusion conformation to provide broader and more durable protection [5].

Furthermore, BRSV infection actively impairs the development of robust cellular immunity, particularly cytotoxic T lymphocyte (CTL) responses. The SH protein, in addition to its effects on innate signaling, also dampens the activation of T cells by reducing the pro-inflammatory cytokine output from antigen-presenting cells, thereby creating a less stimulatory environment for the induction of adaptive T cell responses [18]. Although CD8+ T cells are essential for viral clearance from the lower respiratory tract [21], the virus’s ability to suppress their activation contributes to a prolonged infection course. Moreover, the presence of maternally derived antibodies (MDA) in young calves, while protective against severe disease, presents a major barrier to the development of active immunity from both natural infection and vaccination [1, 26, 28]. This phenomenon is a critical challenge in BRSV control. The presence of MDA can block the processing of viral antigens by B cells and dendritic cells, leading to profound suppression of both humoral and cell-mediated memory responses, a phenomenon known as "original antigenic sin" or antibody-mediated immune suppression [6, 21]. This leaves a window of vulnerability in young calves where passive immunity wanes before active immunity is established, a period when severe disease is most common [6, 28]. The vaccine-induced enhancement of IgA secretion and IFN-γ production, as seen with some adjuvanted modified-live vaccines, is a crucial step towards overcoming these suppressive effects and inducing protective mucosal and systemic immunity [23, 28].

In summary, the molecular pathogenesis of BRSV is a masterclass in immune subversion. The virus not only destroys the physical integrity of the respiratory epithelium but also systematically dismantles the host’s anti-viral defenses. From the direct blockade of NF-κB signaling by the SH protein and the induction of damaging oxidative stress and NETosis, to the hijacking of epithelial surfaces for secondary bacterial adhesion and the constant antigenic evolution of its surface glycoproteins, BRSV employs a multi-layered strategy to ensure its survival, replication, and transmission. This sophisticated interplay between viral virulence factors and the host response is the ultimate driver of the severe and economically devastating disease observed in cattle herds worldwide.

Epidemiology, Transmission, and Risk Factors

Global Distribution and Economic Impact

Bovine respiratory syncytial virus (BRSV) is a ubiquitous pathogen of cattle, recognized as a primary viral agent within the bovine respiratory disease complex (BRDC) across all major cattle-rearing regions of the world [1, 3, 13]. The virus is endemic in North and South America, Europe, and Asia, with seroprevalence studies consistently demonstrating widespread exposure. In Brazil, a study of non-vaccinated dairy herds in São Paulo State reported a seroprevalence of 79.5% using virus neutralization tests, with individual herd prevalence ranging from 40% to 100% [45]. Similarly, in Argentina, feedlot cattle exhibited an individual seroprevalence of 78.64% [48]. In the Middle East, a study in the Nineveh Governorate of Iraq found an alarming 83.11% seroprevalence in non-vaccinated cattle [42], while in Turkey, all 43 herds sampled in the inner Aegean region had at least one seropositive animal, with a true seropositivity of 58.48% after adjustment for test sensitivity [9]. In Europe, herd-level prevalence is similarly high; a Norwegian study found 46.2% of dairy herds were BRSV-positive based on bulk tank milk (BTM) antibody testing [49], while Swedish studies have reported herd prevalences ranging from 73.4% to 82.3% [50]. In China, a large-scale surveillance effort across 16 provinces detected BRSV RNA in 18.65% of nasal swabs from beef cattle with BRDC outbreaks, with positive samples originating from 23 farms across 11 provinces, confirming a wide geographical distribution [7].

The economic consequences of BRSV infection are profound and multifaceted. Direct losses stem from mortality, morbidity, reduced weight gain, decreased feed conversion efficiency, and the costs of treatment and prevention [1, 3]. A landmark longitudinal study in a Norwegian beef herd documented that bulls with severe clinical signs during a BRSV outbreak had a persistently lower weight/age ratio (0.04–0.10 lower) for at least eight months following the acute infection [51]. Even apparently healthy bulls exposed during the outbreak exhibited a reduced growth rate of 111 g/day compared to a cohort from the following year, requiring an additional 23 days to reach reference slaughter weight, and feed conversion was reduced by 79 g weight gain per kilogram of concentrate consumed [51]. These data underscore that production losses extend far beyond the acute phase of illness, often going unrecognized by producers. Furthermore, BRSV is a major driver of antimicrobial use in cattle operations, as secondary bacterial infections are a common sequela, contributing to concerns about antimicrobial resistance [40].

Transmission Dynamics and Viral Shedding

BRSV is transmitted primarily via the respiratory route through direct contact between infected and susceptible animals, as well as through aerosolized droplets over short distances [13, 44]. The virus replicates extensively in the epithelial cells of the upper and lower respiratory tract, with viral antigen detected in nasal, tracheal, bronchial, bronchiolar, and alveolar epithelial cells, as well as in alveolar macrophages [38]. Experimentally, calves begin shedding viral RNA in nasal secretions as early as one day post-exposure, with peak shedding occurring between days 6 and 13 [44]. The duration of viral RNA detection can extend up to 27–28 days post-exposure, but the period during which infective virions can be isolated is considerably shorter, typically confined to the first two weeks of infection [44]. This distinction is critical for understanding transmission risk: while molecular detection (RT-PCR or RT-ddPCR) may remain positive for weeks, the window for active transmission of infectious virus is more limited. Importantly, the total clinical score for respiratory signs correlates well with the magnitude of viral RNA shedding, meaning that clinically ill animals represent the highest transmission risk [44].

A key finding from experimental transmission studies is that naïve calves introduced into a group of infected animals four weeks after the initial exposure remained seronegative and did not become infected, despite the continued detection of viral RNA in the previously infected group [44]. This suggests that the infectious period is largely confined to the acute and early convalescent phase. Furthermore, calves that have recovered from primary infection are protected from reinfection and do not shed virus upon re-exposure for at least seven weeks, indicating the development of a robust, albeit not lifelong, protective immunity [44]. However, natural infections induce long-lasting humoral immunity, with neutralizing antibodies and BRSV-specific IgG1 and IgG2 persisting for at least two years, and in some cases up to four years [5]. Despite this, reinfections do occur, particularly when antibody titers wane, and these reinfections are characterized by milder clinical signs and significantly reduced virus shedding compared to primary infections [5].

Indirect Transmission and Fomite Contamination

The role of indirect transmission via fomites and human personnel is a critical component of BRSV epidemiology, particularly for between-herd spread. A seminal study investigating this route demonstrated that BRSV RNA could be detected on 89% of fomites (clothing, boots, and equipment) 24 hours after exposure to infected calves [43]. However, critically, no infective virions were recovered from these fomites, suggesting that while viral RNA persists, the risk of indirect transmission via contaminated objects may be lower than for some other respiratory viruses [43]. In contrast, for bovine coronavirus (BCoV), infective virions were detected on fomites, highlighting pathogen-specific differences in environmental stability [43].

Human nasal mucosa can also serve as a temporary vehicle for BRSV. Swabs taken from personnel 30 minutes after contact with infected calves were positive for BRSV RNA in 35% of cases, but all samples were negative for infective virus, and the carriage was short-lived, with no RNA detected after six hours [43]. These findings indicate that while human-mediated mechanical transmission is possible, the risk is likely limited unless there is rapid, close contact with susceptible animals. Nevertheless, the Norwegian national control program for BRSV and BCoV emphasizes strict biosecurity measures, including the use of herd-specific clothing and boots, and restrictions on animal movements, to prevent indirect introduction of virus into negative herds [40, 46]. The program’s success, which relies on classifying herds based on antibody testing and preventing virus introduction, demonstrates that improved external biosecurity can be an effective strategy for population-level control [40].

Molecular Epidemiology and Genetic Diversity

Phylogenetic analysis of the BRSV attachment glycoprotein (G) gene has revealed the existence of at least eight distinct genetic subgroups (I–VIII), with subgroup III being the most globally dominant in recent years [7, 14, 17]. In China, all 18 complete G gene sequences obtained from beef cattle between 2020 and 2022 belonged to subgroup III, and these strains exhibited unique evolutionary characteristics, clustering in an independent branch distinct from other Chinese and American strains [7]. Similarly, the first BRSV isolates from Turkey were classified as subgroup III, sharing 99.49% nucleotide identity with a previous Turkish strain but also displaying three novel amino acid substitutions (P89S, D115G, and S165L) in the G protein, indicating ongoing viral evolution [9, 15]. In Brazil, while some strains clustered with subgroup III, the majority of wild-type strains from feedlot cattle were genetically diverse and formed a putative new subgroup, characterized by the replacement of conserved cysteine residues in the central hydrophobic region of the G protein, an area critical for antibody reactivity [14].

The genetic diversity of BRSV has significant implications for vaccine efficacy and diagnostic accuracy. In Croatia, strains belonging to two newly identified subgroups (VII and VIII) were detected over four consecutive years, with subgroup VII strains being replaced by subgroup VIII strains between 2014 and 2016 [17]. Co-circulation of subgroup II and VIII strains was also observed, and the Croatian strains within subgroups II and VII harbored unique mutations within an essential immunodominant region of the G protein, suggesting continuous immune-driven selection [17]. In Norway, sequencing of the G gene from outbreaks between 1976 and 2014 showed that currently circulating strains belong to subgroup II, but an isolate from 1976 formed a separate branch within this subgroup, indicating temporal evolution [24]. Notably, two distinct strains were found circulating in the same geographical area at the same time, with sequence variations concentrated in an antigenically important region of the G protein [24]. Whole-genome sequencing has further refined our understanding of BRSV transmission at a regional scale. Analysis of consensus sequences from natural outbreaks in Sweden revealed 146 polymorphic sites, with the vast majority (144/146) differentiating viruses from different counties, suggesting that whole-genome data can discriminate between circulating isolates from distant areas but lacks sufficient resolution to infer direct transmission routes between closely located herds [8].

Risk Factors for Infection and Disease

A complex interplay of host, pathogen, management, and environmental factors determines the risk of BRSV infection and the severity of ensuing disease.

Age and Maternal Immunity: Young calves are disproportionately affected by severe BRSV disease [1, 3]. This susceptibility is partly due to the waning of maternally derived antibodies (MDA), which are acquired through colostrum ingestion. A classic seroepizootiologic study demonstrated that passive immunity in calves becomes undetectable at an average of 99 days (range 30–208 days), and importantly, this passive immunity fails to protect calves from infection and clinical disease upon exposure [25]. Furthermore, MDA can interfere with the efficacy of modified-live virus (MLV) vaccines, as demonstrated in a meta-analysis where MLV vaccines failed to show significant morbidity reduction when calves were vaccinated in the face of maternal immunity [6]. However, passive immunity from vaccinated dams can provide a significant reduction in clinical signs, particularly severe forms, and reduces BRSV detection in the lower respiratory tract, though it does not prevent nasal virus excretion [26]. Age itself is a significant risk factor; a study in Turkey found that animals over one year of age had 2.36 times higher odds of seropositivity compared to younger animals [9], and a Brazilian study confirmed that adult animals over one year old are an important risk factor for high herd seroprevalence [45]. This reflects the cumulative probability of exposure over time.

Herd Size and Management Type: Herd size is one of the most consistently identified risk factors for BRSV seropositivity. In Turkey, herds with more than 50 animals had 10.32 times higher odds of being BRSV-positive compared to smaller herds [9]. Similarly, in Norway, increasing herd size was associated with increased odds of BRSV seropositivity in BTM [49]. The type of operation also matters; in Turkey, dairy herds had 8.97 times higher odds of seropositivity compared to beef herds, likely due to the continuous introduction of new animals and higher stocking densities in dairy operations [9]. In Iraq, animals from large herds (≥100 animals) had significantly higher seroprevalence than those from smaller herds [42].

Geographic Location and Seasonality: BRSV exhibits distinct spatial clustering. In Norway, isopleth maps revealed large differences in prevalence risk across the study area, with the highest prevalence in the northern region [49]. Spatial analysis showed that the antibody status of one herd is influenced by the status of its neighbors, indicating the importance of local transmission and indirect spread [49]. In Iraq, the northern region of the Nineveh Governorate was associated with the highest prevalence [42]. Seasonality is also a well-documented factor; outbreaks are most common during the winter months when cattle are housed indoors, facilitating close contact and aerosol transmission [13, 41, 42]. In Iraq, samples harvested in winter displayed the highest BRSV antibody titers compared to other seasons [42].

Co-infections and Secondary Bacterial Infections: BRSV is a master facilitator of secondary bacterial pneumonia, a phenomenon central to the pathogenesis of BRDC. The virus enhances bacterial adherence to respiratory epithelial cells through multiple mechanisms. BRSV infection significantly increases the adherence of Pasteurella multocida to bovine lower respiratory tract epithelial cells by upregulating the platelet-activating factor receptor (PAFR) [30]. This effect is site-specific; BRSV replicates more efficiently in cells derived from the lower respiratory tract (bronchus and lung) than the upper respiratory tract (trachea), and it is in these lower tract cells that BRSV-induced enhancement of P. multocida adherence is most pronounced [31]. Conversely, in the upper respiratory tract, BRSV infection decreases P. multocida adherence by downregulating intercellular adhesion molecule-1 (ICAM-1), potentially disrupting a natural barrier to bacterial colonization [34]. BRSV also enhances the attachment of Trueperella pyogenes to infected cells in a multiplicity of infection- and time-dependent manner, an effect mediated directly by the BRSV G protein, which colocalizes with the bacteria on the cell surface [2]. Immunohistochemical studies of naturally occurring pneumonia have confirmed that BRSV is the main pneumonia-inducing agent and an important predisposing factor for Pasteurella spp. infections, with 35% of pneumonic lungs showing dual infection with BRSV and either P. multocida or Mannheimia haemolytica [33]. In Argentina, BRSV-positive pneumonia cases were frequently co-infected with M. haemolytica or bovine viral diarrhea virus 1 [39], and in Brazil, co-infections with Histophilus somni have been documented [47].

Stress and Management Events: Stressful management events, such as weaning, transport, commingling, and castration, are well-established triggers for BRSV outbreaks [1]. These events induce immunosuppression, primarily through the release of corticosteroids, which can reactivate latent infections or increase susceptibility to primary infection. The association between a past history of respiratory disease in a herd and increased BRSV seropositivity (OR = 4.06) highlights the cyclical nature of BRDC in high-risk operations [9]. The introduction of new animals into a herd is a major risk factor for the introduction of new BRSV strains, as demonstrated by a severe outbreak in Italy where a genetically divergent strain (97% similarity to a Scandinavian epizootic strain) was introduced through imported animals, resulting in 39 adult deaths and 12 abortions within three weeks [41].

Immunomodulation by the Virus: BRSV employs sophisticated immune evasion strategies that directly influence transmission dynamics and disease severity. The small hydrophobic (SH) protein of BRSV inhibits the phosphorylation of NF-κB p65, a master transcription factor for pro-inflammatory cytokines, thereby dampening the host's innate immune response and facilitating viral replication [18]. Recombinant BRSV lacking the SH gene (rBRSVΔSH) is attenuated in the lower respiratory tract and induces higher levels of pro-inflammatory cytokines and increased T cell activation, highlighting the SH protein's role in immune modulation [18, 23]. The virus also disrupts the oxidative stress balance; BRSV infection upregulates genes involved in reactive oxygen species (ROS) production (e.g., PTGS2) while reducing antioxidant enzymes in the bronchoalveolar lavage, leading to neutrophil-driven tissue damage and the formation of extracellular traps [32, 36]. This exaggerated neutrophil response, while part of the host defense, contributes significantly to the pathology of BRSV-induced bronchiolitis and interstitial pneumonia [36].

Clinical Signs, Pathology, and Disease Spectrum

The clinical manifestation of bovine respiratory syncytial virus (BRSV) infection exists along a remarkably broad continuum, ranging from subclinical infections detected only through molecular or serological surveillance to a fulminant, fatal respiratory syndrome characterized by acute interstitial pneumonia and profound respiratory compromise. This spectrum is shaped by a complex interplay of host factors, most notably age, immunological naivety, and the presence and titer of maternally derived antibodies, as well as viral factors, including strain virulence and the capacity for immune evasion, and environmental or management-related stressors that precipitate outbreaks [1, 3, 5]. Understanding this intricate and variable clinical and pathological landscape is fundamental to accurate diagnosis, effective intervention, and the design of robust control strategies.

Clinical Signs: From Inapparent Infection to Severe Respiratory Distress

In experimentally infected calves and during natural outbreaks, the incubation period for BRSV is typically short, ranging from two to five days following exposure [22, 44]. The initial clinical signs are often insidious and non-specific, reflecting the early stages of viral replication in the upper respiratory tract. Affected animals frequently present with a significant pyrexia, with rectal temperatures commonly exceeding 40.0°C (104°F) [22, 53, 54]. This febrile response is often accompanied by serous to mucoid nasal discharge, conjunctivitis, and an occasional, soft, dry cough [25, 44, 52]. Anorexia, depression, and a noticeable reduction in feed intake and water consumption are frequently reported, contributing to the immediate and long-term production losses associated with the disease [25, 51].

As the infection progresses and the virus descends into the lower respiratory tract, the clinical picture intensifies. The cough becomes more frequent, moist, and productive, and tachypnea (increased respiratory rate) becomes evident [22, 53]. In moderate to severely affected calves, the respiratory effort becomes markedly labored, with animals exhibiting an forced expiratory grunt, open-mouth breathing, and significant abdominal lift, indicative of severe bronchiolitis and airway obstruction [22, 28]. On auscultation, the normal vesicular breath sounds are replaced by a harsh, bronchial tone, and fine crackles and wheezes may be heard, particularly over the cranioventral lung fields, reflecting the presence of exudate and airway narrowing [22, 38]. In severe cases, particularly those complicated by secondary bacterial bronchopneumonia, cyanosis of the mucous membranes may be observed, signaling profound hypoxemia [10, 41].

The severity of clinical signs is profoundly modulated by the host's immune status. Calves with high levels of maternally derived antibodies (MDA) are often protected against severe disease, though they may still become infected and shed virus, thereby contributing to herd transmission [5, 25, 26]. In contrast, calves with low or absent MDA are highly susceptible to severe clinical disease [22]. Age is another critical determinant, with the most severe clinical outcomes consistently observed in young calves, particularly those under six months of age [1, 56]. The presence of concurrent stressors, such as weaning, transport, commingling, or inclement weather, can dramatically exacerbate clinical signs and precipitate explosive outbreaks [1, 10]. The spectrum can be starkly illustrated by contrasting a mild outbreak, where clinical signs are limited to transient pyrexia and a mild cough with no mortality [25], with a highly pathogenic outbreak caused by a virulent strain. In one such documented outbreak in Italy, an unusual BRSV strain caused a severe flu-like syndrome unresponsive to antibiotics, culminating in 39 adult animal deaths and 12 abortions within three weeks [41]. Similarly, a major outbreak in Northeast China caused by a subgroup III strain resulted in a morbidity rate of 27.42% and a mortality rate exceeding 25% in post-weaning calves [10].

Gross Pathology: The Macroscopic Signatures of BRSV Pneumonia

The pathological lesions observed at necropsy are largely confined to the respiratory tract and reflect the severity and duration of the infection. The upper airways, the trachea and major bronchi, often contain abundant, sometimes foamy, mucoid to mucopurulent exudate [38]. The most characteristic and consistent gross lesions, however, are found in the lungs. The hallmark of BRSV-associated pneumonia is a cranioventral consolidation, affecting the apical, cardiac, and often the cranial portions of the diaphragmatic lung lobes [22, 27, 56]. These consolidated areas are typically firm, dark red to purple, and fail to collapse upon opening the thoracic cavity. They are sharply demarcated from the adjacent, normal, pink, and spongy lung parenchyma.

In severe cases of interstitial pneumonia, a distinct and highly diagnostic pattern emerges. The lungs fail to collapse completely and are diffusely heavy, edematous, and meaty in texture [27, 39]. Widespread, multifocal to coalescing areas of consolidation may affect a significant percentage of the lung parenchyma; in experimental models, mean lesion scores involving up to 48.3% of the lung have been reported [22]. A defining feature of the acute interstitial form is the presence of grossly visible emphysema, which may be interstitial (evident as rows of gas bubbles along interlobular septa and beneath the visceral pleura) or subpleural, creating large, bullous lesions [27, 42]. This emphysema results from air trapping secondary to bronchiolar obstruction and the severe, necrotizing bronchiolitis that characterizes BRSV infection. The presence of extensive emphysema is a critical differentiating feature from the classic cranioventral bronchopneumonia typically associated with primary bacterial pathogens like Mannheimia haemolytica.

Histopathology and Cellular Pathogenesis: The Microscopic Battlefield

The microscopic lesions of BRSV infection are a direct reflection of the virus's profound tropism for the ciliated epithelial cells of the respiratory tract, from the nasal mucosa down to the terminal bronchioles and alveoli [38]. The earliest and most consistent histopathological change is a severe, acute bronchiolitis, characterized by multifocal necrosis and sloughing of the bronchiolar epithelium into the airway lumen [27, 29, 38]. This denuded epithelium is replaced by a neutrophilic and mononuclear inflammatory exudate, which, combined with cellular debris, fibrin, and mucus, forms plugs that obstruct the small airways. This bronchiolar obstruction is the proximate cause of the air trapping, emphysema, and severe respiratory distress seen clinically.

A pathognomonic feature of BRSV infection, and a key diagnostic clue for the pathologist, is the formation of multinucleated syncytial cells. These "giant cells" are formed by the fusion of infected epithelial cells (or macrophages) mediated by the viral fusion (F) protein expressed on the cell surface [29, 38]. Syncytia are most commonly identified within the lumina of bronchioles and in the adjacent alveolar spaces. Within the cytoplasm of these syncytial cells and other infected epithelial cells, one may occasionally find eosinophilic, intracytoplasmic viral inclusion bodies, which are another cardinal histologic feature of the disease [27, 29]. The alveolar interstitium becomes markedly thickened due to the infiltration of mononuclear cells, primarily lymphocytes and macrophages, and by edema and congestion of the alveolar septal capillaries [27, 29, 39]. This interstitial pneumonia often co-exists with the bronchiolar lesions. In severe cases, alveolar septal necrosis can be a prominent feature, a finding that has been statistically associated with BRSV-associated acute interstitial pneumonia (AIP) [27].

The host's immune response, while essential for viral clearance, is a double-edged sword. The inflammatory response is a critical driver of the pathology. An exaggerated neutrophil influx into the airways and interstitium is a hallmark of severe BRSV disease [36, 55]. Proteomic analyses of bronchoalveolar lavage (BAL) fluid from infected calves have revealed a profile dominated by neutrophil activation products, including elevated levels of neutrophil elastase and the presence of citrullinated histone H3, a specific marker of neutrophil extracellular traps (NETs) [36]. This dysregulated neutrophilic response, coupled with a reduction in detectable antioxidant enzymes, suggests that an imbalance between the production of reactive oxygen species (ROS) and their detoxification, a state of oxidative stress, is a major contributor to tissue damage [32, 36]. The transcription of genes related to ROS production (e.g., PTGS2) is significantly upregulated in BRSV-infected cells [32]. Furthermore, the viral non-structural and small hydrophobic (SH) proteins play a critical role in modulating this response; the deletion of the SH protein leads to increased apoptosis and pro-inflammatory cytokine production in vitro, but paradoxically results in reduced pulmonary inflammation in vivo, highlighting the virus's sophisticated strategies for subverting the host immune response to favor its own replication [18, 23].

Disease Spectrum: The Role of Secondary Infections and Long-Term Sequelae

BRSV is rarely a solitary actor in the field; it is a primary and potent instigator of the bovine respiratory disease complex (BRDC). The profound damage inflicted on the respiratory epithelium and mucociliary escalator by the viral infection creates a permissive environment for secondary bacterial invasion. This virus-bacterium synergism is a central theme in the pathogenesis of severe, often fatal, pneumonia. Pasteurella multocida and Mannheimia haemolytica are the most commonly isolated bacterial agents from cases of BRSV-associated pneumonia [2, 33, 56]. Trueperella pyogenes and Histophilus somni are also frequently implicated in these mixed infections [2, 47].

The mechanisms underpinning this synergy are increasingly well-defined. BRSV infection significantly enhances the adherence of these bacteria to respiratory epithelial cells. For Pasteurella multocida, BRSV infection upregulates the expression of the platelet-activating factor receptor (PAFR) on the surface of lower respiratory tract epithelial cells, providing a direct docking site for the bacteria [30]. Conversely, the virus has a differential effect on the upper respiratory tract, where it can downregulate intercellular adhesion molecule-1 (ICAM-1), potentially explaining how the upper airway gate is disrupted [34]. For Trueperella pyogenes, the enhanced adherence is directly mediated by the BRSV G protein, which is expressed on the surface of infected cells and serves as a binding ligand for the bacterium [2]. This increased bacterial load, combined with the virus-induced suppression of local immune defenses, facilitates the development of a fulminant, fibrinosuppurative bronchopneumonia or pleuropneumonia that is the hallmark of severe BRDC [33, 39]. In such cases, the histopathology reveals a complex picture of viral bronchiolitis and interstitial pneumonia overlaid with an intense, necrotizing, and exudative bacterial pneumonia [39].

Beyond the acute mortality and morbidity, BRSV infection exerts significant long-term consequences that are often overlooked. Even in animals that recover from the acute phase, substantial production losses persist. A landmark study from Norway demonstrated that bulls which developed severe clinical signs during a BRSV outbreak had a significantly reduced weight gain and poorer feed conversion that was detectable for at least eight months after the outbreak, long after clinical recovery [51]. Remarkably, even apparently healthy bulls that were exposed to the outbreak but did not develop clinical signs showed a measurable reduction in growth rate compared to unexposed animals [51]. These findings underscore the substantial, insidious economic burden of BRSV, which extends far beyond the immediate costs of treatment and mortality. The virus also induces a robust but not sterilizing immune response. Natural infection confers protection against severe disease upon re-exposure, but it does not prevent reinfection or subsequent virus shedding, allowing the virus to persist and circulate within and between herds [5, 25, 44]. This capacity for reinfection, combined with a limited duration of protection against new infections, is a key factor contributing to the endemic nature of BRSV in many cattle populations [5]. The pathological and clinical picture is thus not a single disease entity, but a dynamic spectrum shaped by viral strain, host immunity, environmental stress, and the critical interplay with secondary bacterial pathogens, leading to outcomes that range from transient and subclinical to devastating and economically crippling.

Diagnostics and Laboratory Surveillance

The accurate and timely diagnosis of Bovine Respiratory Syncytial Virus (BRSV) infection is a cornerstone of effective disease management, epidemiological surveillance, and the evaluation of intervention strategies such as vaccination and antiviral therapy. Given that BRSV is a primary viral agent within the bovine respiratory disease complex (BRDC), its clinical presentation is often indistinguishable from infections caused by other respiratory pathogens, including bovine parainfluenza virus 3 (BPIV3), bovine herpesvirus 1 (BoHV-1), bovine coronavirus (BCoV), and bovine viral diarrhea virus (BVDV) [3, 13, 39]. Consequently, laboratory confirmation is essential not only for individual animal diagnosis but also for herd-level surveillance and the implementation of control programs. The diagnostic landscape for BRSV has evolved considerably, moving from traditional virological and serological methods to highly sensitive molecular techniques and innovative, non-invasive approaches. This section provides an exhaustive analysis of the current state-of-the-art in BRSV diagnostics and laboratory surveillance, integrating insights from pathogenesis, immunology, and molecular epidemiology.

Traditional and Direct Detection Methods

Historically, the diagnosis of BRSV relied on virus isolation (VI) and the direct detection of viral antigens in clinical specimens. Virus isolation, typically performed on cell lines such as Madin-Darby bovine kidney (MDBK) cells, remains a definitive method for confirming the presence of infectious virus. The characteristic cytopathic effect (CPE), which includes the formation of syncytia, is a hallmark of BRSV infection [15, 38]. However, VI is labor-intensive, time-consuming, and often lacks the sensitivity required for detecting low viral loads, particularly in samples from animals with high levels of maternally derived antibodies (MDA) or from chronically infected animals [55]. Furthermore, the success of VI is highly dependent on the quality of the sample, the timing of collection relative to the clinical course, and the maintenance of the cold chain. As noted in early studies, the virus is labile and can be rapidly inactivated, making successful isolation challenging under field conditions [55].

Direct immunofluorescence antibody tests (d-FAT) and immunohistochemistry (IHC) have been instrumental in detecting BRSV antigens directly in tissue sections or exfoliated cells. These techniques provide spatial resolution, allowing for the localization of viral antigens within specific cell types, such as bronchiolar and alveolar epithelial cells, and within syncytial cells [29, 33, 38]. In lung lavage samples, immunofluorescence has been shown to be a valuable tool for diagnosing BRSV, particularly in young calves where serological responses may be blunted by MDA [55]. IHC has been particularly useful in retrospective studies of formalin-fixed, paraffin-embedded lung tissues, enabling the identification of BRSV as a predisposing factor for secondary bacterial infections with Pasteurella multocida and Mannheimia haemolytica [33]. These studies have demonstrated that BRSV antigens are frequently found in the cytoplasm of epithelial cells and within inflammatory exudates, often co-localizing with bacterial antigens, thereby confirming the virus’s role in the pathogenesis of BRDC [2, 30, 33]. While these antigen detection methods are specific, their sensitivity can be variable, and they require specialized equipment and trained personnel.

Molecular Diagnostics: The Gold Standard

The advent of polymerase chain reaction (PCR)-based technologies has revolutionized the diagnosis of BRSV, offering unparalleled sensitivity, specificity, and speed. Reverse transcription PCR (RT-PCR) and its quantitative variant (RT-qPCR) have become the gold standard for detecting BRSV RNA in a variety of sample matrices, including nasal swabs, bronchoalveolar lavage (BAL) fluid, lung tissue, and even exhaled breath condensate (EBC) [7, 39, 57, 58, 62]. The high sensitivity of these assays allows for the detection of viral RNA even in subclinical cases or during the early and late stages of infection when viral shedding is low [44]. For instance, studies using droplet digital RT-PCR (RT-ddPCR) have demonstrated that viral RNA can be detected in nasal swabs for up to 27 days post-exposure, a period considerably longer than the duration of infectious virus shedding, which is typically limited to the first two weeks [44]. This distinction is critical for understanding transmission dynamics and for interpreting positive PCR results in the context of active infection versus residual RNA.

Multiplex RT-qPCR assays have been developed to simultaneously detect BRSV alongside other major BRD viral pathogens, such as BoHV-1 and BPIV3 [62]. These assays are highly efficient, reducing the time and cost of diagnosis while providing a comprehensive etiological picture. The use of locked nucleic acid (LNA) and minor groove binding (MGB) probes in these multiplex formats has further enhanced specificity and sensitivity, achieving detection limits as low as 10² copies of viral RNA per reaction [62]. This level of sensitivity is superior to traditional virus isolation and immunofluorescence, making multiplex RT-qPCR the preferred method for outbreak investigations and routine surveillance [62].

More recently, nanoparticle-assisted PCR (NanoPCR) has emerged as a novel approach to further enhance detection sensitivity. By incorporating nanoparticles into the PCR reaction, this method has been shown to increase the detection limit by an order of magnitude compared to conventional PCR, detecting as few as 1.43 × 10² copies of the BRSV genome [60]. In field evaluations, NanoPCR identified 46.15% of clinical samples as BRSV-positive, compared to only 23.07% by conventional PCR, highlighting its potential for improving diagnostic yield in clinical settings [60].

Serological Surveillance and Immune Correlates

Serological testing remains a cornerstone of herd-level surveillance and epidemiological studies. The detection of BRSV-specific antibodies, primarily IgG1 and IgG2, is indicative of past infection or vaccination. Enzyme-linked immunosorbent assays (ELISAs) and virus neutralization tests (VNTs) are the most commonly employed serological methods [5, 9, 42, 45]. These assays are critical for determining seroprevalence, identifying risk factors for infection, and assessing the efficacy of vaccination programs [9, 42, 45, 48]. For example, large-scale serosurveys in Argentina, Brazil, and Turkey have consistently reported high individual seroprevalence rates, often exceeding 70%, underscoring the endemic nature of BRSV in many cattle populations [42, 45, 48].

A key challenge in serological diagnosis is the interference of maternally derived antibodies (MDA) in young calves. Passive immunity, acquired through colostrum, can persist for an average of 99 days, with some calves retaining detectable antibodies for up to 208 days [25]. These MDA can neutralize vaccine antigens and blunt the active immune response, complicating the interpretation of serological data in young stock [6, 25]. Furthermore, MDA can mask seroconversion following natural infection, making direct virus detection essential for confirming BRSV involvement in outbreaks affecting young calves [55]. Studies have shown that while MDA can reduce clinical severity, they do not prevent infection or viral shedding, and serological diagnosis in this age group must be interpreted with caution [25, 26].

At the herd level, bulk tank milk (BTM) ELISA testing has emerged as a practical and cost-effective tool for surveillance, particularly in dairy operations. BTM testing provides a composite measure of herd-level antibody status and is used in national control programs, such as the Norwegian BRSV/BCoV control program, to classify herds as positive or negative [40, 46, 49]. The probability of disease freedom (PostPFree) can be estimated from BTM results, incorporating data on test sensitivity, animal movements, and local transmission risk, to provide a dynamic assessment of herd status over time [46]. This approach allows for targeted biosecurity measures and has been instrumental in reducing the prevalence of BRSV in regions with high compliance [40].

Advanced and Emerging Diagnostic Technologies

The integration of transcriptomics, proteomics, and metabolomics into BRSV diagnostics is paving the way for a new era of precision medicine. Whole blood transcriptome analysis has revealed distinct gene expression signatures in BRSV-infected calves, even in those displaying only mild clinical signs [58, 59]. Differentially expressed genes (DEGs) associated with interferon signaling, innate immune responses, and cytotoxic T-cell activity have been identified, providing potential biomarkers for subclinical or early-stage infection [58, 59]. Similarly, microRNA (miRNA) profiling in bronchial lymph nodes has identified 119 differentially expressed miRNAs that target genes involved in pathogen recognition and T-cell proliferation, offering another layer of molecular diagnostic potential [11].

Proteomic analysis of bronchoalveolar lavage (BAL) fluid has provided deep insights into the pathogenesis of BRSV. Calves with severe disease exhibit a protein profile characterized by neutrophil activation, reduced antioxidant enzymes, and the presence of citrullinated histone 3, a marker of neutrophil extracellular traps (NETs) [36]. These findings not only illuminate the mechanisms of lung injury but also suggest that specific proteins, such as LZTFL1 and neutrophil-related proteins, could serve as biomarkers for disease severity [36].

Perhaps one of the most innovative developments is the use of near-infrared (NIR) aquaphotomics for the non-invasive detection of BRSV infection. By analyzing the water matrix coordinates (WAMACS) in exhaled breath condensate (EBC), researchers have been able to discriminate between pre-infection and post-infection samples with an accuracy, sensitivity, and specificity exceeding 93% [57]. This technique detects biochemical changes in the aqueous phase of EBC, likely reflecting volatile and non-volatile compounds produced during the host response to infection. This approach holds tremendous promise for developing a rapid, point-of-care diagnostic tool that could be deployed in the field, eliminating the need for sample transport and laboratory processing [57].

Genomic Surveillance and Molecular Epidemiology

Whole-genome sequencing (WGS) and phylogenetic analysis have become indispensable tools for understanding the molecular epidemiology of BRSV. Sequencing of the attachment glycoprotein (G) gene and the fusion (F) protein gene has revealed the existence of multiple genetic subgroups (I-VIII), with subgroup III being the most prevalent globally, including in China, Turkey, and Brazil [7, 9, 10, 14, 15, 17]. The G protein, in particular, is highly variable and contains immunodominant regions that are under selective pressure from the host immune response. Mutations in this region, such as the replacement of conserved cysteine residues, can lead to immune escape and the emergence of new variants [14, 17].

WGS provides a higher resolution for phylogenetic analysis than single-gene sequencing, but its utility for tracing local transmission routes is limited. A comprehensive study using WGS from experimental infections and natural outbreaks in Sweden found that while consensus-level sequences could discriminate between isolates from distant geographic regions, they lacked sufficient diversity to infer direct transmission between herds in close proximity [8]. However, within-sample (sub-consensus) diversity was higher in experimental samples, suggesting that minor variant analysis might offer some potential for transmission inference, though this remains uninformative at the local scale [8]. Despite these limitations, WGS is invaluable for identifying the introduction of novel strains, such as the highly pathogenic variant that caused a severe outbreak in Italy, which was genetically linked to a major epizootic in Scandinavia [41]. Such data are critical for informing biosecurity measures and for understanding the global movement of BRSV strains.

Acute Phase Proteins as Diagnostic and Prognostic Markers

The acute phase response (APR) is a non-specific but sensitive indicator of inflammation, and the measurement of acute phase proteins (APPs) has been explored as a diagnostic and prognostic tool for BRSV. Experimental infections have demonstrated that serum amyloid A (SAA) and haptoglobin (Hp) concentrations increase dramatically following BRSV challenge, peaking around 7-8 days post-infection [54]. The magnitude of the Hp response correlates well with the severity of clinical signs and the extent of lung consolidation, while SAA responds more rapidly to infection [54]. In natural outbreaks, SAA and lipopolysaccharide-binding protein (LBP) were found to be elevated for several weeks, with higher concentrations associated with secondary bacterial infections and a weaker BRSV-specific IgG1 response [61]. These findings suggest that APP profiling could be used to monitor disease progression, predict the likelihood of bacterial co-infection, and evaluate the efficacy of therapeutic interventions.

Vaccination Strategies and Passive Immunity

The Central Paradox: Maternal Antibodies and Vaccine Interference

The development of effective vaccination strategies against bovine respiratory syncytial virus (BRSV) is fundamentally constrained by the complex interplay between active immunization and the passive transfer of maternal immunity. This paradox represents the single most significant obstacle to achieving durable, widespread protection in young calves, the demographic most susceptible to severe BRSV-induced disease. The immune system of the neonatal calf is not a blank slate; rather, it is profoundly shaped by the ingestion of colostrum, which provides a rich supply of maternally derived antibodies (MDA). While these antibodies are essential for survival against a multitude of pathogens, they also possess the capacity to neutralize vaccine antigens, thereby blunting or completely abrogating the desired active immune response [1, 3, 6].

This phenomenon is not merely a laboratory artifact but has demonstrable, real-world consequences. A comprehensive meta-analysis of 14 controlled experimental challenge studies, encompassing 29 individual trials, evaluated the efficacy of commercially available modified-live virus (MLV) and inactivated BRSV vaccines [6]. The analysis revealed a stark dichotomy: MLV vaccines significantly reduced the risk of mortality and morbidity in calves that were seronegative for maternal antibodies at the time of initial vaccination. However, this protective effect vanished when calves were vaccinated in the presence of passive immunity [6]. This finding underscores a critical biological reality: the very antibodies that protect the calf from natural disease can, if present at high enough titers, render vaccination futile. The duration of this interfering passive immunity is variable, with a classic seroepizootiologic study indicating that MDA to BRSV become undetectable in serum after an average of 99 days, but with a wide range extending from 30 to over 200 days [25]. This variability makes it exceptionally difficult to prescribe a universal "window of opportunity" for vaccination.

The Spectrum of Vaccine Platforms: Inactivated, Modified-Live, and Novel Approaches

The BRSV vaccine landscape is populated by a variety of platforms, each with distinct mechanisms of action, advantages, and limitations, particularly concerning the challenge of MDA interference.

Inactivated (Killed) Vaccines: These vaccines contain whole, inactivated virus particles and are typically administered with an adjuvant to boost immunogenicity. Their primary strength is safety, as they cannot revert to virulence. They are frequently formulated as multivalent products, such as the "Pneumo-5" vaccine, which combines inactivated BRSV with bovine viral diarrhea virus (BVDV), bovine herpesvirus type 1 (BoHV-1), and bovine parainfluenza-3 virus (BPI-3V) [63]. The efficacy of inactivated vaccines is thought to be driven primarily by the induction of neutralizing antibodies. The strategic use of inactivated vaccines can be highly effective in a crucial, indirect application: immunizing pregnant dams to boost the levels of BRSV-specific antibodies in their colostrum, thereby enhancing passive immunity for the newborn calf [26].

Modified-Live Virus (MLV) Vaccines: MLV vaccines contain live BRSV that has been attenuated (weakened) so it can replicate to a limited degree in the host without causing severe disease. This replication is a key advantage, as it more closely mimics a natural infection, stimulating a broader and more robust immune response, including both humoral and cell-mediated arms. The ability of MLV vaccines to induce mucosal IgA and a T-cell response, including interferon-gamma (IFN-γ) production, is considered critical for clearing virus from the respiratory tract and providing more durable protection [28]. However, their efficacy is profoundly compromised by high levels of MDA, which directly neutralize the live vaccine virus before it can establish a productive infection and prime the immune system [6]. A promising development is the use of adjuvanted MLV vaccines, which have shown the ability to overcome some degree of MDA interference, providing significant protection against clinical disease and reducing viral shedding by 3-4 fold even when calves were vaccinated at approximately one month of age [28]. This suggests that formulation and delivery can partially mitigate the suppressive effects of passive immunity.

Novel Attenuated Vaccine Candidates: The genetic manipulation of BRSV has opened new avenues for vaccine development that may circumvent some of the traditional obstacles. A particularly compelling candidate is a recombinant BRSV with a deletion of the small hydrophobic (SH) gene (rBRSVΔSH). The SH protein functions as a viroporin and is a key virulence factor, acting to inhibit the phosphorylation of the transcription factor NF-κB p65 in antigen-presenting cells. This inhibition dampens the host's pro-inflammatory cytokine response, effectively "hiding" the virus from the early innate immune system [18]. By deleting the SH gene, the resulting rBRSVΔSH virus is attenuated, particularly in the lower respiratory tract, yet it retains a high level of immunogenicity. Studies have shown that rBRSVΔSH induces higher levels of apoptosis and pro-inflammatory cytokines (TNF-α and IL-1β) in vitro and significantly less pulmonary inflammation in vivo, while still inducing strong and effective protective immunity against a virulent challenge six months later [23]. This rational design approach offers the potential for a live-attenuated vaccine that is both safer and more potent, capable of stimulating immunity even in the face of low-to-moderate levels of MDA.

The Critical Role of Passive Immunity: Protection and Its Limitations

Passive immunity, derived from colostrum, is the cornerstone of neonatal protection against BRSV. The process is straightforward: a newborn calf must ingest high-quality colostrum within the first few hours of life to acquire systemic antibodies. The strategic vaccination of pregnant dams is a well-established method to enhance the titer and specificity of these colostral antibodies. Experimental evidence strongly supports this approach. A controlled study demonstrated that calves fed colostrum from cows vaccinated prepartum with an inactivated BRSV vaccine had a significant reduction in clinical signs, particularly severe disease, following experimental challenge [26].

However, this passive protection is far from absolute and has several critical limitations:

1. Failure to Prevent Upper Respiratory Tract Infection: The most significant finding is that while passive antibodies protect the lower respiratory tract (the lungs), they provide little to no protection against BRSV replication in the upper respiratory tract (nasal passages). Calves with high levels of MDA still shed significant quantities of virus from their nasal mucosa, making them a source of infection for other animals even as they themselves are protected from severe pneumonia [25, 26]. This phenomenon is a major driver of the endemic nature of BRSV, as it allows for silent circulation of the virus within a herd.
2. Interference with Active Immunity: As detailed previously, high-titer MDA neutralizes vaccine antigens, preventing the establishment of active immunological memory. This creates a "protection gap" where maternal antibodies wane, leaving the calf susceptible to natural infection before a vaccine can be effective [6].
3. Duration of Protection: The half-life of maternal IgG is finite. The classic study by Baker et al. (1986) demonstrated that passive antibodies become undetectable in the calf's serum by an average of 99 days [25]. During this entire period, the calf is in a precarious state, protected from severe disease by waning immunity, but unable to be effectively vaccinated.
4. Quantitative and Qualitative Aspects: The level of protection is directly correlated with the titer of antibodies ingested. High-titer colostrum from vaccinated dams provides superior protection [26]. Furthermore, the quality of the antibody response matters. Studies using bovine monoclonal antibodies have shown that neutralizing antibodies directed against the pre-fusion form of the F protein are particularly potent in blocking infection [21]. Natural infection appears to induce a memory response that is stronger against the pre-fusion F protein, a nuance that vaccine developers are actively trying to replicate [5].

Herd-Level Strategies: Vaccination, Biosecurity, and the Way Forward

Given the complexities of individual calf immunity, effective BRSV control must be approached at the population level. This requires a multi-pronged strategy that integrates vaccination with robust biosecurity.

Vaccination strategies must be tailored to the specific epidemiology of the herd. A common, evidence-based approach involves:

• Vaccinating the Dam: This is the most effective method for delivering high-titer, BRSV-specific passive immunity to the newborn calf [26].
• Early Life Vaccination: The advent of intranasal MLV vaccines, which have been shown to be safe and effective when applied from the day of birth, offers a potential solution to the MDA interference problem [52]. By delivering the vaccine directly to the nasal mucosa, it may bypass systemic maternal antibodies and induce local immunity more effectively. Studies showed that this approach significantly reduced viral load in nasal swabs following challenge, even in very young calves [52].
• Boosting Immunity in Replacement Heifers and Adults: To maintain herd immunity and reduce the risk of reinfection and transmission, it is necessary to boost the immunity of adult cattle. This is crucial because while natural infection can induce long-lasting antibodies (lasting at least two years), it does not prevent reinfection, and previously infected adult cattle can play a key role in virus transmission between outbreaks [5]. Regular booster vaccinations are needed to maintain high levels of mucosal immunity and reduce virus shedding.

Ultimately, vaccination alone has proven insufficient to eradicate BRSV, as highlighted by the findings of the Norwegian BRSV/BCoV control program [40]. This program pioneered a population-based approach that prioritized biosecurity over vaccination. The core principle is to classify herds based on antibody testing and then implement strict biosecurity measures to prevent the introduction of the virus into naïve herds. This includes controlling animal movements, using separate clothing and equipment for different barns, and educating personnel on indirect transmission risks. The program demonstrated that the prevalence of BRSV can be dramatically reduced or even eliminated at the herd and regional level without the use of vaccination [40, 46]. This paradigm shift suggests that the most effective long-term strategy may be a combined one: using vaccinations to boost immunity and reduce clinical disease within a herd, while simultaneously implementing rigorous biosecurity to limit virus introduction and circulation between herds.

Viral–Bacterial Interactions in Bovine Respiratory Disease Complex

The pathogenesis of bovine respiratory disease complex (BRDC) is not merely a sequence of independent infections but a highly orchestrated, synergistic interplay between primary viral pathogens, most notably bovine respiratory syncytial virus (BRSV), and opportunistic bacterial invaders. This synergy is the central pillar of BRDC pathogenesis, transforming a self-limiting viral bronchiolitis into a severe, often fatal, fibrinosuppurative bronchopneumonia. The World Organisation for Animal Health (WOAH) and the Food and Agriculture Organization (FAO) recognize BRDC as a primary constraint on global cattle production, and the viral–bacterial axis is the critical driver of this morbidity and mortality. Understanding the molecular and cellular mechanisms of this interaction is essential for developing targeted intervention strategies that move beyond broad-spectrum antimicrobial use.

The Viral Inciting Event and the Opening of the Bacterial Gateway

BRSV acts as the primary inciting agent, creating a permissive environment in the bovine respiratory tract that facilitates the adherence, colonization, and subsequent invasion of bacterial pathogens. The virus does not simply cause direct tissue damage; it actively rewires the host cell surface and the local immune landscape to favor bacterial adhesion. This is a critical concept: BRSV is not merely a bystander that damages the epithelium; it is an active participant in constructing a niche for secondary bacteria.

Historical and contemporary studies consistently demonstrate that BRSV infection is the predominant viral agent identified in pneumonic outbreaks where bacterial pathogens like Pasteurella multocida, Mannheimia haemolytica, Histophilus somni, and Trueperella pyogenes are subsequently isolated [33, 39, 47, 56]. In a seminal study of 14 pneumonia epizootics in dairy calves, BRSV was the viral agent most commonly identified, with P. multocida isolated in 12 of the 14 outbreaks [56]. This epidemiological association is not coincidental; it is mechanistically driven.

Molecular Mechanisms of Enhanced Bacterial Adherence

The most well-characterized molecular mechanisms revolve around the upregulation of host cell adhesion receptors and the direct bridging of bacteria to the virus itself.

The Platelet-Activating Factor Receptor (PAFR) Axis for Pasteurella multocida

A major breakthrough in understanding BRSV–P. multocida synergy came from studies demonstrating that BRSV infection significantly enhances the adherence of P. multocida to bovine lower respiratory tract epithelial cells [31, 35]. The molecular mechanism underlying this enhancement is a virus-induced upregulation of the platelet-activating factor receptor (PAFR) on the surface of bronchial and lung epithelial cells. Proteomic analyses revealed that BRSV infection drives the accumulation of PAFR, and functional experiments using specific PAFR blockade, gene knockdown, and overexpression convincingly demonstrated that P. multocida adherence is directly dependent on PAFR expression levels [30]. This is a classic example of viral manipulation of a host signaling receptor being exploited by a bacterium.

Critically, this interaction is site-specific. While BRSV enhances P. multocida adherence in the lower respiratory tract (bronchus and lung), it does not appear to do so in the upper respiratory tract (trachea). In fact, BRSV infection of upper respiratory tract epithelial cells was shown to downregulate intercellular adhesion molecule-1 (ICAM-1), a molecule involved in the adherence of P. multocida at that site [34]. This suggests a sophisticated pathogenesis: BRSV may facilitate the initial colonization of the upper tract by other mechanisms, but its primary role in severe pneumonia is to create a receptive niche in the lower airways via PAFR upregulation, effectively bypassing host defenses designed to keep bacteria out of the lung parenchyma.

The BRSV G Protein as a Direct Adhesin for Trueperella pyogenes

While P. multocida parasitizes a host receptor, T. pyogenes utilizes a more direct strategy. BRSV infection significantly enhances the adhesion of T. pyogenes to a wide range of cell types in a time- and multiplicity-of-infection-dependent manner [2]. Remarkably, this effect is not dependent on the bacterium’s intracellular invasion ability; it is purely an enhancement of surface attachment.

The critical discovery was that the BRSV attachment glycoprotein (G protein) itself serves as a direct docking site for T. pyogenes. When the G protein was expressed on the surface of cells in the absence of other viral proteins, it was sufficient to enhance bacterial binding. Furthermore, the addition of anti-BRSV G antibodies blocked this enhanced adherence, and immunofluorescence microscopy confirmed colocalization of the BRSV G protein and T. pyogenes on the cell surface [2]. This represents a paradigm of a virus acting as a molecular bridge, providing a novel adhesin for a bacterium that otherwise might have limited ability to bind to intact, healthy epithelium.

Coinfections with Mannheimia haemolytica and Histophilus somni

The interaction is not limited to P. multocida and T. pyogenes. In field cases, BRSV is frequently detected in lung tissue alongside M. haemolytica and H. somni. In a study of feedlot cattle in Argentina, lung samples from animals with fatal pneumonia were positive for BRSV and M. haemolytica co-infection [39]. Similarly, in a Brazilian feedlot, the nucleic acids of both H. somni and BRSV were identified in nasopharyngeal swabs and pulmonary fragments of animals that died with evidence of bronchopneumonia and interstitial pneumonia [47]. These findings underscore that BRSV creates a broadly permissive environment for a spectrum of opportunistic bacterial pathogens, each of which may exploit distinct but convergent mechanisms of enhanced adherence.

Immune Modulation and the Failure of Bacterial Clearance

Beyond direct effects on adhesion, BRSV profoundly suppresses local innate immune responses that are critical for controlling bacterial proliferation. This creates a two-pronged attack: the virus not only helps the bacteria stick, but also disarms the host’s ability to clear them.

The BRSV small hydrophobic (SH) protein is a key immunomodulatory factor. This viroporin inhibits the phosphorylation of NF-κB p65 in antigen-presenting cells (macrophages and dendritic cells), thereby dampening the production of pro-inflammatory cytokines like TNF-α and IL-1β in response to both viral infection and bacterial lipopolysaccharide (LPS) stimulation [18]. This suppression of the early innate alarm signals delays the recruitment and activation of neutrophils and other phagocytes, which are essential for eliminating bacteria before they establish a foothold. The SH protein, therefore, actively prevents the host from mounting the robust inflammatory response needed to contain the viral–bacterial onslaught.

Furthermore, the virus-inflicted damage to the epithelium and the subsequent influx of neutrophils are not entirely beneficial. While neutrophils are needed for bacterial killing, an exaggerated, dysregulated neutrophilic response can be pathogenic. Proteomic analysis of bronchoalveolar lavage from BRSV-infected calves reveals a profile characterized by neutrophil activation, the generation of extracellular traps (NETosis), and a reduction in antioxidant enzymes [36]. This leads to collateral tissue damage from reactive oxygen species and proteolytic enzymes, further compromising the epithelial barrier and creating more surface area for bacterial adherence. The acute phase protein response, particularly a dramatic rise in haptoglobin and serum amyloid A (SAA), correlates with the severity of lung consolidation and clinical signs, and secondary bacterial infections can further amplify this response, creating a vicious cycle of inflammation and tissue destruction [54, 61].

Therapeutic and Prophylactic Implications

The detailed knowledge of these viral–bacterial interactions points toward novel intervention strategies. For instance, supplementation with Saccharomyces cerevisiae fermentation products (SCFP) was shown to reduce clinical disease scores, lung pathology, and, notably, the incidence of secondary bacterial infections in BRSV-challenged calves [53]. This was associated with a modulation of the immune response, including reduced airway neutrophil recruitment and reduced virus-specific IL-17 secretion by T cells in the bronchoalveolar lavage. The mechanism likely involves a more balanced innate immune response that limits the virus-induced damage and subsequent bacterial invasion rather than a direct antiviral effect.

Conversely, the use of non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen requires careful consideration. While ibuprofen can reduce fever and inflammation, its use without concurrent antiviral therapy was associated with increased viral shedding [12, 20]. In the context of viral–bacterial synergy, an increase in viral load could potentially lead to greater upregulation of PAFR and more extensive G protein display on the cell surface, thereby exacerbating bacterial adherence. The best outcomes were observed when an antiviral fusion protein inhibitor (FPI) was combined with ibuprofen, suggesting that controlling the viral driver of the synergy is paramount [12, 20].

In conclusion, BRSV is not merely a predisposing factor for bacterial pneumonia; it is an active, molecular architect of the disease. Through direct adhesion mechanisms (e.g., G protein for T. pyogenes), indirect receptor upregulation (e.g., PAFR for P. multocida), and profound immune evasion (e.g., SH protein), BRSV creates a perfectly fertile environment for secondary bacterial invaders. Deconstructing these precise interactions at the molecular level is the key to developing rational therapies and vaccines that can break this pathogenic synergy and reduce the global reliance on antibiotics for the control of BRDC.

Immunology, Host Responses, and One Health Perspectives

The interplay between Bovine Respiratory Syncytial Virus (BRSV) and the host immune system is a complex, multifaceted dynamic that dictates the trajectory of infection, from subclinical clearance to severe bronchiolitis and pneumonia. This section provides an exhaustive analysis of the innate and adaptive immune mechanisms engaged during BRSV infection, the sophisticated viral strategies for immune evasion, the resultant immunopathology, and the profound implications of this knowledge within a One Health framework, given the virus’s close relationship with human respiratory syncytial virus (HRSV).

Innate Immune Recognition and the Antiviral State

The initial host defense against BRSV is orchestrated by pattern recognition receptors (PRRs) that detect pathogen-associated molecular patterns (PAMPs). Upon infection, the host cell’s PRRs, including Toll-like receptors (TLRs) and RIG-I-like receptors (RLRs), recognize viral RNA and proteins, triggering downstream signaling cascades that converge on the activation of transcription factors such as NF-κB and interferon regulatory factors (IRFs) [1]. This activation is critical for the induction of type I interferons (IFN-α/β) and a cascade of pro-inflammatory cytokines and chemokines. Transcriptomic analyses of whole blood from experimentally infected calves have revealed a robust upregulation of genes associated with the innate immune response, including those within the “Influenza A” pathway, “defense response to virus,” and “regulation of viral life cycle” [58]. Similarly, analysis of the bronchial lymph node transcriptome has identified the enrichment of pathways such as interferon signaling and pathogen recognition receptors, underscoring the central role of these innate sensors in initiating the antiviral state [59].

However, BRSV has evolved potent mechanisms to subvert this early response. A key viral antagonist is the small hydrophobic (SH) protein, a viroporin that plays a critical role in immune evasion. Research has demonstrated that the BRSV SH protein directly inhibits the phosphorylation of NF-κB p65, a master regulator of pro-inflammatory cytokine production. By blocking this step, the virus dampens the expression of cytokines such as TNF-α and IL-1β in antigen-presenting cells (APCs), including monocytes, macrophages, and dendritic cells [18]. This suppression of the innate response is a double-edged sword; while it allows for enhanced viral replication, it also limits the early recruitment and activation of immune cells. The importance of this evasion mechanism is highlighted by studies using a recombinant BRSV lacking the SH gene (rBRSVΔSH). This deletion mutant induces significantly higher levels of pro-inflammatory cytokines and apoptosis in vitro and is attenuated in the lower respiratory tract of calves, yet it remains highly immunogenic, inducing robust protective immunity [23]. This demonstrates that the SH protein is not essential for replication but is a critical virulence factor that tempers the host’s innate inflammatory response.

Oxidative Stress and the Acute Phase Response

A hallmark of BRSV pathogenesis is the induction of oxidative stress and a pronounced acute phase response. Infection triggers a significant increase in the transcription of genes involved in the production and regulation of reactive oxygen species (ROS), such as PTGS2, in both in vitro and ex vivo bovine respiratory tract cells [32]. This oxidative burst, while part of the host’s antimicrobial arsenal, contributes directly to tissue damage. Proteomic analysis of bronchoalveolar lavage (BAL) fluid from infected calves reveals a protein profile dominated by neutrophil activation and a concurrent reduction in antioxidant enzymes, indicating a severe disequilibrium between ROS production and detoxification [36]. This imbalance is further exacerbated by the formation of neutrophil extracellular traps (NETs), as evidenced by the detection of citrullinated histone 3 exclusively in the BAL of non-vaccinated, infected animals [36]. While NETs can trap pathogens, their excessive formation contributes to airway obstruction and epithelial injury.

Concurrently, BRSV infection induces a robust acute phase protein (APP) response. Serum concentrations of haptoglobin (Hp) and serum amyloid A (SAA) rise dramatically, peaking around 7–8 days post-infection, with magnitudes comparable to or exceeding those seen in bacterial infections [54]. This APP response is not merely a bystander effect; the magnitude and duration of the haptoglobin response correlate strongly with the severity of clinical signs (fever) and the extent of lung consolidation [54]. Furthermore, in natural outbreaks, elevated levels of SAA and lipopolysaccharide binding protein (LBP) at later stages of disease are associated with lower BRSV-specific IgG1 production, suggesting that a heightened inflammatory response to secondary bacterial infections can suppress the adaptive antiviral response [61]. This interplay between viral-induced oxidative stress, neutrophil activity, and the acute phase response is a central driver of the immunopathology observed in severe BRSV disease.

Adaptive Immunity: The Balance Between Protection and Pathology

The adaptive immune response is essential for clearing BRSV infection and providing long-term protection. Neutralizing antibodies, particularly those targeting the fusion (F) and attachment (G) glycoproteins, are considered a primary correlate of protection against severe disease [3, 21]. Natural infection induces long-lasting humoral immunity, with BRSV-specific IgG1, IgG2, and neutralizing antibodies persisting for at least two years, and in some cases up to four years [5]. Importantly, memory responses are significantly stronger against the pre-fusion conformation of the F protein compared to the post-fusion form, a finding with critical implications for vaccine design [5]. While passive transfer of neutralizing monoclonal antibodies can protect calves from challenge [21], maternally derived antibodies (MDA) present a significant obstacle to vaccination. High levels of MDA can interfere with the development of active immunity following vaccination, particularly with modified-live virus (MLV) vaccines, often resulting in a failure to reduce morbidity [6]. However, some adjuvanted MLV vaccines have shown efficacy even in the face of MDA, stimulating mucosal IgA responses and IFN-γ production, which are crucial for protection [28].

Cell-mediated immunity, particularly the activity of CD8+ cytotoxic T lymphocytes (CTLs), is indispensable for viral clearance from the lower respiratory tract [3, 21]. Transcriptomic studies of bronchial lymph nodes from infected calves have identified the upregulation of pathways critical for CTL function, including granzyme B signaling and interferon signaling [59]. Furthermore, the microRNA (miRNA) transcriptome in these lymph nodes is profoundly altered, with differentially expressed miRNAs predicted to target genes involved in T cell responses and the proliferation of cytotoxic T cells [11]. Despite this, systemic T cell responses are often difficult to detect following natural infection, and the virus can persist in the face of a seemingly robust antibody response [5]. This suggests that the virus effectively limits the induction or maintenance of strong systemic cellular immunity, favoring a humoral response that, while protective against severe disease, does not always prevent reinfection or virus shedding [5, 25].

Viral Immune Evasion: A Multifaceted Arsenal

BRSV employs a sophisticated array of strategies to evade host immunity, ensuring its survival and transmission. Beyond the SH protein’s inhibition of NF-κB, the virus manipulates the host response at multiple levels. The G protein, in addition to its role in attachment, acts as a decoy antigen, diverting the immune response away from more conserved and vulnerable epitopes on the F protein. Furthermore, the G protein directly enhances the adherence of secondary bacterial pathogens like Trueperella pyogenes and Pasteurella multocida to infected epithelial cells [2, 30, 35]. This is mediated through the upregulation of cellular receptors such as the platelet-activating factor receptor (PAFR) on lower respiratory tract cells [30] and the modulation of intercellular adhesion molecule-1 (ICAM-1) on upper respiratory cells [34]. This viral-bacterial synergy is a cornerstone of the bovine respiratory disease complex (BRDC), where a primary viral infection predisposes the lung to severe, often fatal, bacterial pneumonia [33, 39, 47].

Genetic and antigenic variation is another key evasion tactic. The G protein, in particular, is highly variable, with mutations accumulating in its immunodominant central conserved region. This allows the virus to escape pre-existing antibody responses, leading to the emergence of new genetic subgroups. Studies have identified a wide array of BRSV subgroups (I-VIII) circulating globally, with subgroup III being dominant in China and Turkey, while novel subgroups (VII, VIII) have been identified in Croatia [7, 9, 10, 14, 17]. This continuous evolution poses a significant challenge for vaccine development, as vaccines based on older strains may offer suboptimal protection against newly emerging field isolates. The virus also modulates the host’s epigenomic landscape. ATAC-Seq analysis of bronchial lymph nodes from infected calves has identified thousands of differentially accessible chromatin regions, many of which are located within previously identified BRD susceptibility loci [64]. This suggests that BRSV infection can alter the host’s regulatory DNA landscape, potentially influencing the expression of genes involved in immune function and disease resistance.

One Health Perspectives: The Bovine Model for Human RSV

The BRSV-cattle system is arguably the most relevant and powerful animal model for studying HRSV infection in humans. The two viruses share a high degree of genetic, antigenic, and pathogenic homology, causing nearly identical clinical syndromes, bronchiolitis and pneumonia, in their respective juvenile hosts [1, 3, 21]. Unlike semi-permissive models like mice, calves are a natural host for BRSV, faithfully recapitulating the full spectrum of human disease, including the role of MDA, the development of vaccine-enhanced disease, and the complex interplay with secondary bacterial infections [21, 22]. This translational value is immense. Insights gained from studying BRSV immune evasion mechanisms, such as the role of the SH protein in modulating NF-κB [18, 23] or the impact of oxidative stress on lung pathology [32, 36], are directly applicable to HRSV research. Furthermore, the evaluation of novel therapeutics, such as fusion protein inhibitors (FPIs) and non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, in the BRSV calf model provides critical preclinical data for human drug development [12, 20].

From a broader One Health perspective, BRSV is a significant pathogen in its own right, causing substantial economic losses to the global cattle industry through morbidity, mortality, reduced weight gain, and treatment costs [1, 51]. The virus is endemic in most cattle-producing regions, with seroprevalence often exceeding 70-80% [42, 45, 48]. Effective control strategies are therefore a priority for both animal health and agricultural sustainability. The Norwegian control program for BRSV and bovine coronavirus (BCoV) serves as a pioneering example of a population-based approach. This voluntary program relies on classifying herds based on antibody testing and implementing strict biosecurity measures to prevent virus introduction, rather than relying on vaccination [40]. This strategy, which aligns with WOAH (World Organisation for Animal Health) principles for disease control, has demonstrated that it is possible to reduce the prevalence of these endemic viruses through improved external biosecurity, thereby reducing antimicrobial use and improving animal welfare. The success of such programs underscores the need for a shift from reactive treatment to proactive prevention, a concept that is equally critical for managing respiratory viruses in human populations. The continued surveillance for emerging BRSV variants, as highlighted by the identification of highly pathogenic strains in Italy and novel subgroups in Brazil and Croatia [14, 17, 41], is essential for informing vaccine updates and maintaining the efficacy of control measures. Ultimately, the study of BRSV immunology and host responses is not merely a veterinary concern; it is a critical component of a unified strategy to combat respiratory viral diseases across species, directly benefiting both human and animal health.

References

[1] Barcelos LdS, Ford AK, Frühauf MI, Botton NY, Fischer G, Maggioli MF. Interactions Between Bovine Respiratory Syncytial Virus and Cattle: Aspects of Pathogenesis and Immunity. Viruses. 2024. DOI: https://doi.org/10.3390/v16111753

[2] Yamamoto S, Okumura S, Kobayashi R, Maeda Y, Takahashi F, Tanabe T. Bovine respiratory syncytial virus enhances the attachment of Trueperella pyogenes to cells. Journal of Veterinary Medical Science. 2024. DOI: https://doi.org/10.1292/jvms.24-0068

[3] Makoschey B, Berge A. Review on bovine respiratory syncytial virus and bovine parainfluenza – usual suspects in bovine respiratory disease – a narrative review. BMC Veterinary Research. 2021. DOI: https://doi.org/10.1186/s12917-021-02935-5

[4] Fix J, Descamps D, Galloux M, Ferret C, Bouguyon E, Zohari S, et al.. Screening antivirals with a mCherry-expressing recombinant bovine respiratory syncytial virus: a proof of concept using cyclopamine. Veterinary Research. 2023. DOI: https://doi.org/10.1186/s13567-023-01165-x

[5] Hägglund S, Näslund K, Svensson A, Lefverman C, Enül H, Pascal L, et al.. Longitudinal study of the immune response and memory following natural bovine respiratory syncytial virus infections in cattle of different age. PLoS ONE. 2022. DOI: https://doi.org/10.1371/journal.pone.0274332

[6] Martínez DA, Newcomer B, Passler T, Chamorro M. Efficacy of Bovine Respiratory Syncytial Virus Vaccines to Reduce Morbidity and Mortality in Calves Within Experimental Infection Models: A Systematic Review and Meta-Analysis. Frontiers in Veterinary Science. 2022. DOI: https://doi.org/10.3389/fvets.2022.906636

[7] Chang Y, Yue H, Tang C. Prevalence and Molecular Characteristics of Bovine Respiratory Syncytial Virus in Beef Cattle in China. Animals. 2022. DOI: https://doi.org/10.3390/ani12243511

[8] Johnson PC, Hägglund S, Näslund K, Meyer G, Taylor G, Orton R, et al.. Evaluating the potential of whole-genome sequencing for tracing transmission routes in experimental infections and natural outbreaks of bovine respiratory syncytial virus. Veterinary Research. 2022. DOI: https://doi.org/10.1186/s13567-022-01127-9

[9] İnce ÖB, Şevik M, Özgür EG, Sait A. Risk factors and genetic characterization of bovine respiratory syncytial virus in the inner Aegean Region, Turkey. Tropical Animal Health and Production. 2021. DOI: https://doi.org/10.1007/s11250-021-03022-5

[10] Jia S, Yao X, Yang Y, Niu C, Zhao Y, Zhang X, et al.. Isolation, identification, and phylogenetic analysis of subgroup III strain of bovine respiratory syncytial virus contributed to outbreak of acute respiratory disease among cattle in Northeast China. Virulence. 2021. DOI: https://doi.org/10.1080/21505594.2021.1872178

[11] Johnston D, Earley B, McCabe M, Kim J, Taylor JF, Lemon K, et al.. Elucidation of the Host Bronchial Lymph Node miRNA Transcriptome Response to Bovine Respiratory Syncytial Virus. Frontiers in Genetics. 2021. DOI: https://doi.org/10.3389/fgene.2021.633125

[12] Lebedev M, McEligot HA, Mutua V, Walsh P, Chaigneau FRC, Gershwin L. Analysis of lung transcriptome in calves infected with Bovine Respiratory Syncytial Virus and treated with antiviral and/or cyclooxygenase inhibitor. PLoS ONE. 2021. DOI: https://doi.org/10.1371/journal.pone.0246695

[13] Prieksat P, Thompson J. bovine respiratory syncytial virus infection. CABI Compendium. 2022. DOI: https://doi.org/10.1079/cabicompendium.91747

[14] Leme RA, Agnol AMD, Balbo L, Pereira FL, Possatti F, Alfieri A, et al.. Molecular characterization of Brazilian wild-type strains of bovine respiratory syncytial virus reveals genetic diversity and a putative new subgroup of the virus. Veterinary Quarterly. 2020. DOI: https://doi.org/10.1080/01652176.2020.1733704

[15] Yazici Z, Ozan E, Tamer C, Muftuoglu B, Barry G, Kuruçay H, et al.. Circulation of Indigenous Bovine Respiratory Syncytial Virus Strains in Turkish Cattle: The First Isolation and Molecular Characterization. Animals. 2020. DOI: https://doi.org/10.3390/ani10091700

[16] Timurkan M, Aydın H, Sait A. Identification and Molecular Characterisation of Bovine Parainfluenza Virus-3 and Bovine Respiratory Syncytial Virus - First Report from Turkey. Journal of Veterinary Research. 2019. DOI: https://doi.org/10.2478/jvetres-2019-0022

[17] Krešić N, Bedeković T, Brnić D, Šimić I, Lojkić I, Turk N. Genetic analysis of bovine respiratory syncytial virus in Croatia.. Comparative Immunology, Microbiology & Infectious Diseases. 2018. DOI: https://doi.org/10.1016/j.cimid.2018.09.004

[18] Pollock N, Taylor G, Jobe F, Guzman E. Modulation of the transcription factor NF-κB in antigen-presenting cells by bovine respiratory syncytial virus small hydrophobic protein. Journal of General Virology. 2017. DOI: https://doi.org/10.1099/jgv.0.000855

[19] Ren J, Nettleship J, Harris G, Mwangi W, Rhaman N, Grant C, et al.. The role of the light chain in the structure and binding activity of two cattle antibodies that neutralize bovine respiratory syncytial virus. Molecular Immunology. 2019. DOI: https://doi.org/10.1016/j.molimm.2019.04.026

[20] Walsh P, Lebedev M, McEligot HA, Mutua V, Bang H, Gershwin L. A randomized controlled trial of a combination of antiviral and nonsteroidal anti-inflammatory treatment in a bovine model of respiratory syncytial virus infection. PLoS ONE. 2020. DOI: https://doi.org/10.1371/journal.pone.0230245

[21] Guzman E, Taylor G. Immunology of bovine respiratory syncytial virus in calves.. Molecular Immunology. 2015. DOI: https://doi.org/10.1016/j.molimm.2014.12.004

[22] Blodörn K, Hägglund S, Gavier-Widén D, Éléouët J, Riffault S, Pringle J, et al.. A bovine respiratory syncytial virus model with high clinical expression in calves with specific passive immunity. BMC Veterinary Research. 2015. DOI: https://doi.org/10.1186/s12917-015-0389-6

[23] Taylor G, Wyld S, Valarcher J, Guzman E, Thom M, Widdison S, et al.. Recombinant bovine respiratory syncytial virus with deletion of the SH gene induces increased apoptosis and pro-inflammatory cytokines in vitro, and is attenuated and induces protective immunity in calves. Journal of General Virology. 2014. DOI: https://doi.org/10.1099/vir.0.064931-0

[24] Klem T, Rimstad E, Stokstad M. Occurrence and phylogenetic analysis of bovine respiratory syncytial virus in outbreaks of respiratory disease in Norway. BMC Veterinary Research. 2014. DOI: https://doi.org/10.1186/1746-6148-10-15

[25] Baker JC, Ames TR, Markham R. Seroepizootiologic study of bovine respiratory syncytial virus in a dairy herd.. American Journal of Veterinary Research. 1986. DOI: https://doi.org/10.2460/ajvr.1986.47.02.240

[26] Meyer G, Foret-Lucas C, Delverdier M, Cuquemelle A, Secula A, Cassard H. Protection against Bovine Respiratory Syncytial Virus Afforded by Maternal Antibodies from Cows Immunized with an Inactivated Vaccine. Vaccines. 2023. DOI: https://doi.org/10.3390/vaccines11010141

[27] Chien RC, Sorensen NJ, Payton M, Confer A. Comparative Histopathology of Bovine Acute Interstitial Pneumonia and Bovine Respiratory Syncytial Virus-Associated Interstitial Pneumonia.. Journal of Comparative Pathology. 2022. DOI: https://doi.org/10.1016/j.jcpa.2022.01.005

[28] Kolb EA, Buterbaugh RE, Rinehart C, Ensley D, Perry G, Abdelsalam K, et al.. Protection against bovine respiratory syncytial virus in calves vaccinated with adjuvanted modified live vaccine administered in the face of maternal antibody.. Vaccine. 2020. DOI: https://doi.org/10.1016/j.vaccine.2019.10.015

[29] Kamdi B, Singh R, Singh V, Singh S, Kumar P, Singh KP, et al.. Immunofluorescence and molecular diagnosis of bovine respiratory syncytial virus and bovine parainfluenza virus in the naturally infected young cattle and buffaloes from India. Microbial Pathogenesis. 2020. DOI: https://doi.org/10.1016/j.micpath.2020.104165

[30] Sudaryatma PE, Saito A, Mekata H, Kubo M, Fahkrajang W, Mazimpaka E, et al.. Bovine Respiratory Syncytial Virus Enhances the Adherence of Pasteurella multocida to Bovine Lower Respiratory Tract Epithelial Cells by Upregulating the Platelet-Activating Factor Receptor. Frontiers in Microbiology. 2020. DOI: https://doi.org/10.3389/fmicb.2020.01676

[31] Sudaryatma PE, Mekata H, Kubo M, Subangkit M, Goto Y, Okabayashi T. Co-infection of epithelial cells established from the upper and lower bovine respiratory tract with bovine respiratory syncytial virus and bacteria.. Veterinary Microbiology. 2019. DOI: https://doi.org/10.1016/j.vetmic.2019.06.010

[32] Hofstetter A, Sacco R. Oxidative stress pathway gene transcription after bovine respiratory syncytial virus infection in vitro and ex vivo.. Veterinary Immunology and Immunopathology. 2019. DOI: https://doi.org/10.1016/j.vetimm.2019.109956

[33] Yaman T, Büyükbayram H, Özyildiz Z, Terzi F, Uyar A, Keleş Ö, et al.. Detection of Bovine Respiratory Syncytial Virus, Pasteurella Multocida, and Mannheimia Haemolytica by Immunohistochemical Method in Naturally-infected Cattle. Journal of Veterinary Research. 2018. DOI: https://doi.org/10.2478/jvetres-2018-0070

[34] Sudaryatma PE, Saito A, Mekata H, Kubo M, Fahkrajang W, Okabayashi T. Bovine Respiratory Syncytial Virus Decreased Pasteurella multocida Adherence by Downregulating the Expression of Intercellular Adhesion Molecule-1 on the Surface of Upper Respiratory Epithelial Cells. Veterinary Microbiology. 2020. DOI: https://doi.org/10.1016/j.vetmic.2020.108748

[35] Sudaryatma PE, Nakamura K, Mekata H, Sekiguchi S, Kubo M, Kobayashi I, et al.. Bovine respiratory syncytial virus infection enhances Pasteurella multocida adherence on respiratory epithelial cells. Veterinary Microbiology. 2018. DOI: https://doi.org/10.1016/j.vetmic.2018.04.031

[36] Hägglund S, Blodörn K, Näslund K, Vargmar K, Lind S, Mi J, et al.. Proteome analysis of bronchoalveolar lavage from calves infected with bovine respiratory syncytial virus, Insights in pathogenesis and perspectives for new treatments. PLoS ONE. 2017. DOI: https://doi.org/10.1371/journal.pone.0186594

[37] Otomaru K, Ogawa R, Oishi S, Iwamoto Y, Hong H, Nagai K, et al.. Effect of Beta-Carotene Supplementation on the Serum Oxidative Stress Biomarker and Antibody Titer against Live Bovine Respiratory Syncytial Virus Vaccination in Japanese Black Calves. Veterinary Sciences. 2018. DOI: https://doi.org/10.3390/vetsci5040102

[38] Castleman W, Jc L, Dubovi E, Do S. Experimental bovine respiratory syncytial virus infection in conventional calves: light microscopic lesions, microbiology, and studies on lavaged lung cells.. American Journal of Veterinary Research. 1985. DOI: https://doi.org/10.2460/ajvr.1985.46.03.547

[39] Ferella A, Streitenberger N, Aguirreburualde MSP, Santos MDD, Fazzio L, Quiroga M, et al.. Bovine respiratory syncytial virus infection in feedlot cattle cases in Argentina. Journal of Veterinary Diagnostic Investigation. 2023. DOI: https://doi.org/10.1177/10406387231182106

[40] Stokstad M, Klem T, Myrmel M, Oma V, Toftaker I, Østerås O, et al.. Using Biosecurity Measures to Combat Respiratory Disease in Cattle: The Norwegian Control Program for Bovine Respiratory Syncytial Virus and Bovine Coronavirus. Frontiers in Veterinary Science. 2020. DOI: https://doi.org/10.3389/fvets.2020.00167

[41] Giammarioli M, Mangili P, Nanni A, Pierini I, Petrini S, Pirani S, et al.. Highly pathogenic Bovine Respiratory Syncytial virus variant in a dairy herd in Italy. Veterinary Medicine and Science. 2020. DOI: https://doi.org/10.1002/vms3.312

[42] Hussain K, Al-Farwachi M, Hassan S. Seroprevalence and risk factors of bovine respiratory syncytial virus in cattle in the Nineveh Governorate, Iraq. Veterinary World. 2019. DOI: https://doi.org/10.14202/vetworld.2019.1862-1865

[43] Oma V, Klem T, Tråvén M, Alenius S, Gjerset B, Myrmel M, et al.. Temporary carriage of bovine coronavirus and bovine respiratory syncytial virus by fomites and human nasal mucosa after exposure to infected calves. BMC Veterinary Research. 2018. DOI: https://doi.org/10.1186/s12917-018-1335-1

[44] Klem T, Sjurseth SK, Sviland S, Gjerset B, Myrmel M, Stokstad M. Bovine respiratory syncytial virus in experimentally exposed and rechallenged calves; viral shedding related to clinical signs and the potential for transmission. BMC Veterinary Research. 2019. DOI: https://doi.org/10.1186/s12917-019-1911-z

[45] Hoppe IBAL, Medeiros AS, Arns C, Samara SI. Bovine respiratory syncytial virus seroprevalence and risk factors in non-vaccinated dairy cattle herds in Brazil. BMC Veterinary Research. 2018. DOI: https://doi.org/10.1186/s12917-018-1535-8

[46] Toftaker I, Ågren E, Stokstad M, Nødtvedt A, Frössling J. Herd level estimation of probability of disease freedom applied on the Norwegian control program for bovine respiratory syncytial virus and bovine coronavirus. Preventive Veterinary Medicine. 2018. DOI: https://doi.org/10.1016/j.prevetmed.2018.07.002

[47] Headley SA, Balbo L, Alfieri A, Saut J, Baptista AL, Alfieri A. Bovine respiratory disease associated with Histophilus somni and bovine respiratory syncytial virus in a beef cattle feedlot from Southeastern Brazil. Semina-ciencias Agrarias. 2017. DOI: https://doi.org/10.5433/1679-0359.2017V38N1P283

[48] Ferella A, Aguirreburualde MSP, Margineda C, Aznar N, Sammarruco A, Santos MDD, et al.. Bovine respiratory syncytial virus seroprevalence and risk factors in feedlot cattle from Córdoba and Santa Fe, Argentina.. Revista Argentina de Microbiología. 2017. DOI: https://doi.org/10.1016/j.ram.2017.07.004

[49] Toftaker I, Sánchez J, Stokstad M, Nødtvedt A. Bovine respiratory syncytial virus and bovine coronavirus antibodies in bulk tank milk – risk factors and spatial analysis. Preventive Veterinary Medicine. 2016. DOI: https://doi.org/10.1016/j.prevetmed.2016.09.003

[50] Wolff C, Emanuelson U, Ohlson A, Alenius S, Fall N. Bovine respiratory syncytial virus and bovine coronavirus in Swedish organic and conventional dairy herds. Acta Veterinaria Scandinavica. 2015. DOI: https://doi.org/10.1186/s13028-014-0091-x

[51] Klem T, Kjæstad HP, Kummen E, Holen H, Stokstad M. Bovine respiratory syncytial virus outbreak reduced bulls’ weight gain and feed conversion for eight months in a Norwegian beef herd. Acta Veterinaria Scandinavica. 2015. DOI: https://doi.org/10.1186/s13028-016-0190-y

[52] Rooij MHv, Schmitz M, Meessen JM, Wouters PAWM, Vrijenhoek M, Makoschey B. Vaccination of calves at day of birth with attenuated vaccines against bovine respiratory syncytial virus, bovine parainfluenza type 3 virus and respiratory bovine coronavirus. Veterinary Vaccine. 2023. DOI: https://doi.org/10.1016/j.vetvac.2023.100014

[53] Mahmoud A, Slate J, Hong S, Yoon I, McGill J. Supplementing a Saccharomyces cerevisiae fermentation product modulates innate immune function and ameliorates bovine respiratory syncytial virus infection in neonatal calves. Journal of Animal Science. 2020. DOI: https://doi.org/10.1093/jas/skaa252

[54] Heegaard P, Godson D, Toussaint M, Tjørnehøj K, Larsen L, Viuff B, et al.. The acute phase response of haptoglobin and serum amyloid A (SAA) in cattle undergoing experimental infection with bovine respiratory syncytial virus. Veterinary Immunology and Immunopathology. 2000. DOI: https://doi.org/10.1016/S0165-2427(00)00226-9

[55] Kimman T, Zimmer G, Straver P, Leeuw PDd. Diagnosis of bovine respiratory syncytial virus infections improved by virus detection in lung lavage samples.. American Journal of Veterinary Research. 1986. DOI: https://doi.org/10.2460/ajvr.1986.47.01.143

[56] Baker JC, Werdin RE, Ames TR, Markham R, Larson VL. Study on the etiologic role of bovine respiratory syncytial virus in pneumonia of dairy calves.. Journal of the American Veterinary Medical Association. 1986. DOI: https://doi.org/10.2460/javma.1986.189.01.66

[57] Santos-Rivera M, Woolums AR, Thoresen M, Meyer F, Vance C. Bovine Respiratory Syncytial Virus (BRSV) Infection Detected in Exhaled Breath Condensate of Dairy Calves by Near-Infrared Aquaphotomics. Molecules. 2022. DOI: https://doi.org/10.3390/molecules27020549

[58] Johnston D, Earley B, McCabe M, Kim J, Taylor JF, Lemon K, et al.. Messenger RNA biomarkers of Bovine Respiratory Syncytial Virus infection in the whole blood of dairy calves. Scientific Reports. 2021. DOI: https://doi.org/10.1038/s41598-021-88878-1

[59] Johnston D, Earley B, McCabe MS, Lemon K, Duffy C, McMenamy M, et al.. Experimental challenge with bovine respiratory syncytial virus in dairy calves: bronchial lymph node transcriptome response. Scientific Reports. 2019. DOI: https://doi.org/10.1038/s41598-019-51094-z

[60] Liu Z, Li J, Liu Z, Li J, Li Z, Wang C, et al.. Development of a nanoparticle-assisted PCR assay for detection of bovine respiratory syncytial virus. BMC Veterinary Research. 2019. DOI: https://doi.org/10.1186/s12917-019-1858-0

[61] Orro T, Pohjanvirta T, Rikula U, Huovilainen A, Alasuutari S, Sihvonen L, et al.. Acute phase protein changes in calves during an outbreak of respiratory disease caused by bovine respiratory syncytial virus. Comparative Immunology, Microbiology & Infectious Diseases. 2009. DOI: https://doi.org/10.1016/j.cimid.2009.10.005

[62] Thonur L, Maley M, Gilray J, Crook TC, Laming E, Turnbull D, et al.. One-step multiplex real time RT-PCR for the detection of bovine respiratory syncytial virus, bovine herpesvirus 1 and bovine parainfluenza virus 3. BMC Veterinary Research. 2012. DOI: https://doi.org/10.1186/1746-6148-8-37

[63] Fadeel MRAE, El-Dakhly A, Allam A, Farag T, El-Kholy AA. Preparation and efficacy of freeze-dried inactivated vaccine against bovine viral diarrhea virus genotypes 1 and 2, bovine herpes virus type 1.1, bovine parainfluenza-3 virus, and bovine respiratory syncytial virus. Clinical and experimental vaccine research. 2020. DOI: https://doi.org/10.7774/cevr.2020.9.2.119

[64] Johnston D, Kim J, Taylor JF, Earley B, McCabe MS, Lemon K, et al.. ATAC-Seq identifies regions of open chromatin in the bronchial lymph nodes of dairy calves experimentally challenged with bovine respiratory syncytial virus. BMC Genomics. 2021. DOI: https://doi.org/10.1186/s12864-020-07268-5